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Chapter 1 of this manuscript is a literature review that serves as an introduction 
to the entire dissertation.  Chapter 2 examines the effects of the melatonin injection on 
heart rate and rhythmicity in Drosophila melanogaster Canton-S (wild-type) pupae and 
pupae bearing a variety of heart mutations.  Chapter 3 investigates further the possible 
mechanisms of melatonin’s ability to increase heart rhythmicity without significantly 
affecting heart rate.  A melatonin antagonist, luzindole; a high-affinity melatonin 
agonist, 2-iodomelatonin and RNAi techniques are used to identify a possible melatonin 
receptor in Drosophila melanogaster. 
An appendix contains a previously published manuscript detailing experiments 
performed at the beginning of my graduate studies before I began my work with 
melatonin.  The paper is entitled The Relationship of Heart Function to Temperature in 
Drosophila melanogaster and its Heritability (Jennings et al., 2009).
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INTRODUCTION 
 
MELATONIN AND ITS EFFECTS ON VERTEBRATE AND INVERTEBRATE 
PHYSIOLOGY 
Cardiovascular disease is the leading cause of death (~598,000 per year) in the 
United States (Heron, 2013), thus elucidating causes is of principal importance for 
public health. Furthermore, there are several categories of this disease, including 
cardiomyopathy, conduction defects, hypertension, atherosclerosis, and venous 
malformations, many of which are caused by genes that are conserved and may act in 
common physiological processes or pathways (Bier & Bodmer, 2004).  Acute coronary 
occlusion is the leading cause of morbidity and mortality in the Western world. 
According to the World Health Organization, it will be the major cause of death in the 
world by the year 2020 (Lopez & Murray, 1998).  Cardiac events can result in damage 
to the intrinsic pacemaker cells of the heart, causing a variety of cardiac arrhythmias.  
Postoperative atrial fibrillation (AF) is a specific type of arrhythmia that is the most 
common complication after cardiac surgery (Zeriouh et al., 2014).  Furthermore, it is 
well understood that cardiac arrhythmias are a common and often lethal manifestation of 
many acquired and inherited diseases affecting the cardiovascular system.  
Electrophysiologists have long sought to understand and treat the arrhythmogenic 
mechanisms of these diseases to sustain life and improve its quality (Delisle et al., 
2004). 
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Drosophila as a model organism for the study of cardiovascular disease 
The study of heart development and physiology in Drosophila melanogaster is 
intensifying rapidly as it continues to expand as a model system for studying cardiac 
problems generally and genetic influences in particular.  Findings in the fly are directly 
applicable to the human heart as a growing number of genes have been identified with 
homologous function in both organisms (Bier & Bodmer, 2004).   Although heart 
structure in Drosophila is very different from that of vertebrates, many of the basic 
elements for cardiac specification and differentiation are conserved.  Of the 1682 human 
disease genes currently known, 74% have homologs in Drosophila and nearly a third of 
these genes (~500) are as highly conserved as genes known to be functionally equivalent 
between flies and humans (Bier & Bodmer, 2004). These Drosophila genes include 
homologs of genes causing a broad spectrum of human diseases ranging from 
neurological disorders and cancer to developmental defects, metabolic/storage disorders, 
cardiovascular disease, as well as genes required for function of the visual, auditory, and 
immune systems (Reiter et al., 2001).   Because of the simplicity in its structure and 
availability of powerful genetic tools, the Drosophila heart has emerged as a model 
system for unraveling the basic genetic and molecular mechanisms of cardiac 
development, function, and aging (Qian et al., 2007).   
Anatomy and physiology of the Drosophila heart 
The Drosophila heart, or dorsal vessel, is located medially and dorsally in the 
hemocoel and transports hemolymph through the larval and adult body cavity (Miller, 
1950; Rizki, 1978; Curtis et al., 1999).  The anterior third of the dorsal vessel forms the 
aorta.  The posterior segment, or heart proper, contains three pairs of openings called 
ostia to admit hemolymph (Rizki, 1978; Curtis et al., 1999; Wasserthal, 2007).  Heart 
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pacemaking in Drosophila is myogenic (Dowse et al., 1995; Gu & Singh, 1995; Bodmer 
et al., 2005), and originates from a caudal pacemaker (Rizki, 1978), an assembly of ion 
channels, including those passing Ca2+ and K+, interacting in an oscillatory manner 
(Dowse et al., 1995; Johnson et al., 1998; Bodmer et al., 2005).   The possibility of a 
second, more anterior pacemaker in the region of the cardiovascular valve is suggested 
by reversals in contraction seen occasionally in larvae and consistently in early pupae 
(McCann, 1969; Rizki, 1978). Heartbeat is triphasic, consisting of contraction (systole), 
relaxation (diastole), and pause (diastasis) (Jones, 1977; Rizki, 1978; Curtis et al., 1999; 
Wasserthal, 2007). Heart rate is determined by the duration of diastasis (Markou & 
Theophilidis, 2000) and is modulated by temperature (Irisawa et al., 1993; Dowse et al., 
1995), small peptide hormones (Johnson et al., 2000), and neurotransmitters (Miller, 
1985; Dascal et al., 1986; Johnson et al., 1997; Hille, 2001).  Cardioactive substances 
alter heart rate and rhythmicity by altering pacemaker ion channel kinetics either by 
direct binding or indirect modulation through signaling pathways (Johnson et al., 1997; 
Johnson et al., 2000; Johnson et al., 2002).  
Four ion channel genes have been identified as necessary for normal heartbeat 
through analysis of mutant heartbeat and pharmacology (Johnson et al., 1998; Johnson et 
al., 2000).  Three of the channels allow the passage of K+ and the other carries a Ca2+ 
current (Johnson et al., 2000).  Johnson et al. (1997, 1998) proposed a model for the 
Drosophila cardiac pacemaker based on genetic and pharmacological data:  A delayed-
rectifier potassium channel current (IKr) containing an α subunit encoded by ether à go-
go (eag) (Kaplan & Trout, 1969; Warmke et al., 1991a; Engel & Wu, 1992; 
Brüggemann et al., 1993) creates a hyperpolarizing leak.  The decay of the 
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hyperpolarizing K+ efflux has the effect of depolarizing sino-atrial cells so that a 
voltage-gated calcium channel, the α1 subunit of which may be encoded by cacophony 
(cac) (Von Schilcher, 1976; Smith et al., 1996; Smith et al., 1998), opens to allow Ca2+ 
to enter the cell.  This current is blocked by -conotoxin (-CgTx) MVIIC, an 
antagonist of N- (Ashcroft, 2000; Hille, 2001) and P/Q-type calcium channels, and 
importantly this agent is effective at disrupting the normal heartbeat of Drosophila 
(Olivera et al., 1994).  Subsequently, this influx of calcium opens a calcium-activated 
potassium channel encoded by slowpoke (Elkins et al., 1986) and blocked by 
charybdotoxin (CTX) (Moczydlowski et al., 1988), and a fast voltage-gated potassium 
channel (KV, A-type) encoded by Shaker (Sh) (Kaplan & Trout, 1969; Warmke & 
Ganetzky, 1994) and blocked by 4-aminopyridine (4-AP) (Thompson, 1977; 
Moczydlowski et al., 1988; Engel & Wu, 1992).  The efflux of potassium repolarizes the 
membrane (Thompson, 1977; Elkins et al., 1986; Fozzard, 1986; Irisawa et al., 1993; 
Littleton & Ganetzky, 2000; Lipsius et al., 2001).  The eag channel is also activated by 
the calcium depolarization, but in a more delayed fashion.  The K+ current carried by 
this channel type eventually triggers the pacemaker potential, thereby recommencing the 
oscillatory process. 
Mutations affecting heart function in Drosophila 
 As noted above, there are several genes in Drosophila that encode ion channels 
and calcium signaling pathways involved in pacemaker function of the heart.  Human 
homologues of these genes have also been identified.  The gene ether à-go-go (eag)  
(Brüggemann et al., 1993) encodes a K
+
 channel (Kaplan & Trout, 1969; Warmke et al., 
1991; Bruggemann et al., 1993; Silverman et al., 2003).  Flies bearing the eag mutant 
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exhibited heart beating irregularity at several test temperatures (Johnson et al., 1998).  
This gene has a homologue in humans known as HERG (Human eag Related Gene) 
(Warmke & Ganetzky, 1994), and mutations at this locus result in a cardiac 
arrhythmicity--Chromosome 7-linked long QT (LQT2) syndrome (Keating & 
Sanguinetti, 1996; Sanguinetti et al., 1996).  Mutations in the kumbakharna gene in the 
fly, encoding the Sarcoplasmic Endoplasmic Reticulum Calcium ATPase (SERCA) 
produce severe cardiac defects (Sanyal et al., 2006) while several diseases that arise 
from defective SERCA function have been described in mammals; cardiac disorders are 
known to be associated with reduced SERCA2a function in cardiac muscles of higher 
vertebrates (MacLennan, 2000; Periasamy & Huke, 2001).  It is well known that 
potassium channels are central to generation and possibly conduction of the heartbeat in 
Drosophila.  Slowpoke (slo) is a mutation which encodes the pore-forming structural 
portion of a Ca2+ activated K+ channel in Drosophila melanogaster (Atkinson et al., 
1991).  The role of the Ca2+-dependent K+ current (ICF) is particularly critical in 
pacemaking of the heart (Johnson et al., 1998).  The mutation slo virtually eliminates 
heartbeat by abolishing ICF (Elkins et al., 1986; Johnson et al., 1998).  Pallanck & 
Ganetzky (1994), report the cloning of mouse and human homologs of the Drosophila 
melanogaster calcium-activated potassium channel gene, slowpoke (slo). Both the 
human and mouse genes encode polypeptides that have more than 50% amino acid 
identities with their Drosophila counterpart. no action potential temperature sensitive (napts) is 
a recessive mutation that affects the level of sodium channel activity and, at high 
temperature, causes paralysis associated with a loss of action potentials.   napts is a gain-
of-function allele of  maleless (mle), a gene required for X chromosome dosage 
compensation and male viability (Kernan et. al, 1991).  napts slows heartbeat and renders 
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it less rhythmic and prevents the heart from responding to temperature with an altered 
rate (Dowse et al., 1995).  mle is highly homologous to human RNA helicase A and the 
bovine counterpart of RNA helicase A, nuclear helicase II, proteins implicated in the 
unwinding of RNA (Lee et al., 1997).  The mutation dunce (dnc1), encodes a cAMP-
specific phosphodiesterase (PDE), which has adverse effects on learning and memory in 
Drosophila.  cAMP-PDE also interacts with the calcium-calmodulin signaling pathway. 
This signaling pathway is also modulated by melatonin (Turjanski et al., 2004).  
Modulation of this signaling pathway changes the concentration of intracellular calcium.  
Calcium signaling is vital to heart function in both Drosophila and humans.  Four 
human genes (DPDE1 through DPDE4) are closely related to the dnc locus of 
Drosophila (Bolger et al., 1993).  
Homologies between vertebrate and Drosophila heart development 
These parallels extend to heart development.  The discovery of the homeobox 
transcription factor Tinman in Drosophila and its conservation in vertebrates provided 
the first evidence that heart development was controlled by homologous pathways in the 
animal kingdom (Bodmer, 1993; Azpiazu & Frasch, 1993).  The NK-2 type homeobox-
containing gene tinman (tin) (Kim & Nirenberg, 1989), is essential for early molecular 
events initiating cardiac  development in Drosophila (Bodmer, 1993; Bier & Bodmer, 
2004).  A tin homolog, NKX2-5, has been strongly implicated as the cause of a 
developmental atrial septal defect and atrioventricular nodal dysfunction (Schott et al., 
1998). The key determinants of cardiogenesis in the fly also play fundamental roles in 
early cardiac specification in the vertebrates, and they do so in similar ways (Bier & 
Bodmer, 2004).   For example, in flies and vertebrates, Dpp/bone morphogenetic protein 
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(BMP)-TGF-h signals cross germ layers to maintain Tinman/NKX2-5 expression 
(Frasch, 1995; Schultheiss et al., 1997; Lockwood & Bodmer, 2002).   A similar 
relationship exists between Tinman/NKX2-5 and Pannier/GATA-4 (Klinedinst & 
Bodmer, 2003; Garg et al., 2003).  Moreover, mutations have been identified in humans 
in many of these conserved heart-specifying genes, such as NKX2-5, GATA-4, and 
TBX-5, which cause various forms of congenital heart disease (Basson et al., 1997; 
Schott et al., 1998; Garg et al., 2003).  Because the control of early cardiac development 
and function is likely to be carried out by conserved networks of target genes, many 
congenital heart diseases, even those for which a major player has been identified, are 
likely to be multigenic (Ranade et al., 2003; Kraft & de Andrade, 2003). 
      Of particular interest to me are the effects of the indolamine melatonin (N-acetyl-
5-methoxytryptamine) on the pacemaker of Drosophila melanogaster.  
Neurotransmitters and neurohormones are central to control of heart function in 
Drosophila.  Prior research in our lab has shown that heart rate in the pupa of D. 
melanogaster is significantly increased by serotonin (5-hydroxytryptamine, 5-HT) 
(Johnson et al., 1998).  Furthermore, four 5-HT receptors have been identified and 
sequenced in Drosophila melanogaster, strongly indicating a physiological purpose for 
this neurotransmitter (Saudou et al., 1992; Colas et al., 1995).    
      Because of the strong antagonistic relationship between serotonin and melatonin 
in regulating circadian rhythms (see below), and the fact that they are both synthesized 
from similar precursors, my interests focus on the effects that melatonin might have on 
the pacemaker activity and heart function of  D. melanogaster.  It was hypothesized that 
the acceleratory effect of serotonin would be paired with a deceleratory effect by 
melatonin.  Surprisingly, unpublished studies of D. melanogaster and melatonin 
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performed by Evelyn Powers and me between 2009 and the present have shown that 
melatonin has no significant effect on heart rate, but significantly increases rhythmicity 
in hearts that were either beating normally or substantially arrhythmic before treatment 
with melatonin.   
Melatonin 
        In 1958, Lerner et al. successfully isolated a substance from pineal extracts, 
which had been shown to lighten the skin color of tadpoles, frogs, toads, and fish 
(McCord & Allen, 1917; Kitay & Altschule, 1954).  Melatonin, a ubiquitously present, 
low molecular weight molecule in living organisms, has a simple structure; however, it 
exhibits pleiotropic biological activities in species from bacteria to mammals (Hardeland 
et al., 2011).  In vertebrates, the roles of melatonin are numerous and include: regulating 
circadian rhythm and acting as a neuromodulator, hormone, cytokine and biological 
response modifier (Man et al., 2011; Reiter, 1991).  It also affects brain, immune, 
gastrointestinal, cardiovascular, renal, bone and endocrine functions, and acts as an 
oncostatic and anti-aging molecule (Yu et al., 1993; Pandi-Perumal et al., 2008; 
Slominski et al., 2008; Leja-Szpak et al., 2010; Celinski et al., 2011).  Some of these 
activities are receptor-mediated, including via melatonin membrane receptors and 
nuclear receptors (Reppert, 1997; Dubocovich et al., 1999; Dubocovich & Markowska, 
2005; Imbesi et al., 2009; Shiu et al., 2010).  Other functions are melatonin receptor 
independent (Reiter, 1996; Tan et al., 2002) including the interactions of melatonin with 
reactive oxygen species (ROS) and those mediated by its bioactive metabolites (Silva et 
al., 2004, 2005; Mayo et al., 2005; Manda et al., 2007, 2008; Hardeland et al., 2009; 
Schaefer & Hardeland 2009).  Melatonin is an indolamine which is biologically 
synthesized from the amino acid L-Tryptophan.  Serotonin is a precursor to melatonin.  
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Melatonin release in mammals, birds and reptiles varies in a daily cycle, as does 
serotonin, and is well known for its key role in regulating circadian rhythms.  In 
mammals, a circadian clock in the suprachiasmatic nucleus (SCN) of the hypothalamus 
receives information from the retina about environmental light.  The clock controls a 
rhythm of the enzyme hydroxyindole-O-methyltransferase (HIOMT), which O-
methylates N-acetylserotonin to produce melatonin in the final step of melatonin 
synthesis.  This information passes through the neural circuits of the superior cervical 
ganglia and controls rhythmic melatonin release by the pineal gland.  Melatonin then 
travels through the blood stream and binds to melatonin receptors located throughout the 
body.  Melatonin levels are highest at night, when serotonin levels are at their lowest.  
As we are exposed to daylight, serotonin levels increase and melatonin levels decline.   
    In addition to the pineal gland, some melatonin is synthesized in the Harderian 
gland of rats (Bubenik et al., 1976), retina of chickens (Iuvone et al., 2002), bone 
marrow of rats and humans (Conti et al., 2000), gastrointestinal tract of humans, birds 
and rodents (Lee & Pang, 1993) and lacrimal glands of Syrian hamsters (Mhatre et al., 
1988).  Rat and pig studies by Bubenik et al., 1996 confirmed early findings of Huether 
and coworkers (1992) that concentrations of melatonin are substantially higher in 
gastrointestinal tract tissues than in plasma.  Interestingly, at any time of the day or 
night, the gut of humans contains at least 400 times more melatonin than the pineal 
gland (Chen et al., 2011).   In humans endogenous melatonin is released from the pineal 
gland into the bloodstream and then into other bodily fluids, including cerebral spinal 
fluid, saliva, and bile (Head, 2005).  Blood (endogenous) melatonin is mainly bound to 
albumin (70%) and to a lesser extent to orosomucoid (Morin et al., 1997).   
10 
 
Orosomucoid is a glycoprotein in the blood plasma that functions in carrying lipophilic 
compounds, such as melatonin.  Circulating melatonin can reach all body tissues and is 
able to cross the blood–brain barrier to modulate brain activity (Hirata et al., 1974).   
  During the day human serum concentrations of the hormone are low (10-20 
pg/ml), and significantly increase at night (80-120 pg/ml) with peak between 24:00 and 
03:00 h.  The onset of secretion is usually around 21:00-22:00 h and the offset at 07:00-
09:00 h (Karasek et al., 1998).   
  Exogenous melatonin is rapidly absorbed in humans when taken orally and peak 
serum levels are observed at 60-150 minutes.  Peak concentrations after oral dosing of 
80mg of crystalline melatonin are significantly higher (350 to 10,000 times) than those 
seen with endogenous melatonin secretion (Waldhauser et al., 1984).  Exogenous plasma 
melatonin displays a short half-life.  Kinetic studies of circulating melatonin following 
intravenous or subcutaneous bolus administration demonstrated an elimination phase 
with a half –life (t ½) of 44 minutes in humans (Iguichi et al., 1982), 30 minutes in 
rhesus monkeys (Reppert et al., 1979), 20 to 24 minutes in rats (Ozaki et al., 1976; 
Gibbs & Vriend, 1981; Chan et al., 1984), and 13 to 14 minutes in Syrian hamsters 
(Vaughan et al., 1986).  Endogenous melatonin is mainly metabolized in the liver to 6-
OH-melatonin and excreted as conjugates of sulfuric and glucuronic acid (Kveder, 
1961).  About 90% of endogenous melatonin is excreted in urine as 6-
sulfatoxymelatonin (aMT6s) with a plasma half-life of 10–45 minutes (Arendt, 1995).  
Exogenous and endogenous melatonin are both metabolized and excreted via the same 
pathways, but the bioavailability of exogenous melatonin from an oral dose ranges from 
10-56 percent.    
11 
 
The low bioavailability of exogenous melatonin is thought to be a consequence of 
hepatic first-pass extraction, which converts melatonin to its metabolite before it enters 
the systemic circulation (Di et al., 1997).    
Melatonin receptors 
 There have been two membrane bound melatonin receptors identified and 
characterized in humans, MT1 and MT2. MT1 was known as Mel1a, and MT2 as Mel1b 
( Dubocovich et al., 2010, 1998).  Both of them belong to the family of G protein-
coupled, seven transmembrane receptors (GPCRs) (Dubocovich et al., 2003; Witt-
Enderby et al., 2003).  However, melatonin is also lipophilic, which allows it to enter the 
nucleus directly and bind to nuclear receptors in the RORα/RZR family (Slominski et 
al., 2012).   
  In humans, MT1 receptors are expressed in the brain, cardiovascular system 
(including peripheral blood vessels, aorta and heart), immune system, testes, ovary, skin, 
liver, kidney, adrenal cortex, placenta, breast, retina, pancreas and spleen (Dubocovich 
& Markowska, 2005; Fischer et al., 2008; Pandi-Perumal et al., 2008; Slominski et al., 
2005, 2008).  In the brain, the receptor is predominantly found in the hypothalamus, 
cerebellum, hippocampus, substantia nigra and ventral tegmental area (Pandi-Perumal et 
al., 2008).  MT2 receptors have been found in the immune system, brain (hypothalamus, 
suprachiasmatic nucleus (SCN)), retina, pituitary, blood vessels, testes, kidney, 
gastrointestinal tract, mammary glands, adipose tissue, and the skin (Dubocovich et al., 
2005; Reppert et al., 1995; Roca et al., 1996; Slominski et al., 2005).   It is highly likely 
that if the melatonin receptor is present in D. melanogaster, it will also be a GPCR.   
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At present, 35 GPCRs are functionally characterized in Drosophila.  Another 14 
receptors are predicted to be involved in neuropeptide signaling pathways, but their 
ligands are still unknown and therefore they are classified as “orphan” receptors (Caers 
et al., 2012).     
Effects of melatonin 
 Melatonin’s many effects in humans include its hypnotic/sedative effects, its 
ability to shift circadian rhythms when administered at appropriate times of the day, its 
ability to modulate the immune system by increasing T lymphocyte, natural killer cell, 
eosinophil and cytokine production (Lissoni et al., 1993), and its ability to slow cancer 
growth by inhibiting mitosis and inducing apoptosis of some cancer cells (Blask et al., 
2002).  Melatonin is a powerful antioxidant that stimulates gene expression and 
activities of superoxide dimutase, catalase, and glutathione peroxidase; all of which play 
a role in the metabolism of H2O2 which ultimately results in reducing the formation of 
the devastatingly toxic OH radical (Reiter, 1996).  Owing to its antioxidant properties, 
melatonin also shows beneficial anti-aging effects in rats (Poeggeler, 2005). Melatonin 
may also act at the level of the mitochondrial respiratory chain to reduce electron 
leakage and, therefore, free radical generation (Reiter et al., 2002).  The cardio- 
protective effects of melatonin (Tan et al., 2002) are of particular interest and will be 
discussed in more detail shortly. 
 Early melatonin research focused on its synthesis and metabolic pathways, 
specifically in relation to its day/night cycle, its improvement of thyroid function in peri-
menopausal and menopausal women, its ability to lighten skin pigmentation in 
amphibians (McCord & Allen, 1917; Kitay & Altschule, 1954), its beneficial effects on 
behavioral and sleep disorders in human subjects, and its key roles in the modulation of 
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the endocrine system including regulation of GnRH (gonadotrophin releasing hormone) 
release, stimulation of oxytocin secretion, promotion of progesterone synthesis release, 
regulation of cortisol production, and promotion of androgen production (Balík et al., 
2004; Schaeffer & Sirotkin, 1997; Tamura et al., 2008, 2009).  Models used in early 
research included predominately humans and avian species, but most research on 
melatonin and its cardiovascular effects in mammals has been carried out in humans and 
rats.   
  Since the identification of melatonin by Lerner et al. (1958), it has been shown 
that melatonin is involved in the regulation of many physiological systems, including the 
cardiovascular system (Vazan et al., 2003;2005).  Minimal research has been done on 
the effects of exogenous melatonin in the human cardiovascular system.  The results 
obtained thus far show that melatonin improves cardiovascular health, however, the 
question remains as to whether melatonin’s effects on cardiovascular function are 
antioxidant in nature or receptor mediated.  It is well known that melatonin is a potent 
antioxidant, even more powerful than vitamins C and E.  In 2002, Reiter and Tan 
showed that melatonin exhibits cardio-protective effects in rat hearts exposed to 
ischemia and then re-perfused.  Cagnaccie et al., (1998) and Arangino et al., (1999) 
found that the oral administration of melatonin in comparison to placebo was able to 
reduce blood pressure, vascular reactivity (vasorelaxant effect), and catecholamines in 
healthy young women and men.  These data suggest that melatonin administration may 
induce beneficial effects on the circulation of humans and subjects may be protected 
against cardiovascular accidents with regular melatonin supplementation.  In the study 
completed by Cagnacci et al., (1998), the cardiovascular effects induced by the daytime 
administration of melatonin (1 mg) were compared with those of placebo in 17 young, 
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healthy, early follicular-phase women. Compared with placebo, the administration of 
melatonin modified, within 90 min, the pulsatility index (PI) of the internal carotid 
artery, abdominal aorta, and axillary artery.  The pulsatility index is a measure of the 
variability of blood velocity in a vessel evaluated by color Doppler ultrasound.   In a 
subsequent, two day study (Arangino et al., 1999), 14 normal, healthy men were given 
either 1 mg of melatonin or placebo on Day 1 and then, on Day 2, received the opposite 
treatment  (as compared to the treatment they received on Day 1).  Ninety minutes after 
supplementation on both days the researchers measured blood flow in a blood vessel 
(PI) in the arm as well as blood pressure in both groups.  The administration of 
melatonin significantly reduced blood pressure, the PI in the internal carotid artery, and 
catecholamine levels within 90 minutes.  Melatonin reduces blood pressure in young 
men (Arangino et al. 1999), reduces myocardial contractility via a specific cardiac 
receptor in rat papillary muscle (Abete et al., 1997), and increases the antioxidant 
(glutathione peroxidase) activity in the plasma and erythrocytes of spontaneously 
hypertensive rats (Girouard et al., 2004).  In addition, decreased melatonin levels were 
reported in various pathological conditions including hypertension with “nondipper 
pattern” (which means that blood pressure is independent of the sleep-wakefulness 
cycle), aggravation of heart failure, ischemic heart disease, and in patients after acute 
myocardial infarction (Paulis & Simko, 2007).  Also, patients with coronary heart 
disease have lower than normal melatonin levels (Dominguez-Rodriguez & Abreu-
Gonzalez, 2010).  Interestingly, incidence of sudden cardiac death is high in the morning 
hours when melatonin levels are low (Sahna et al., 2006).   
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Melatonin mechanisms of action 
 The mechanisms by which melatonin exerts its protective effects are not clearly 
understood.  It is evident that melatonin is a very powerful antioxidant, and therefore has 
the ability to scavenge free radicals that can damage tissues.  In recent years, research 
has shifted its focus to melatonin’s powerful antioxidant properties as they relate to 
cardiovascular health.  Melatonin is a powerful scavenger of reactive oxygen species 
(ROS), including the hydroxyl (Reiter, Tan et. al., 1998) and peroxyl radicals (Pieri et 
al., 1994) as well as singlet oxygen (Sewerynek et al., 1996) and nitric oxide (Noda et 
al., 1999).  ROS are known to play a role in the formation of neurodegenerative and 
cardiovascular disease and cancer.  The possibility exists that melatonin may have the 
ability to prevent such disease processes.  In addition to scavenging ROS, melatonin 
stimulates the antioxidant enzymes superoxide dismutase, glutathione peroxidase, and 
catalase (Head, 2005).  Melatonin was also able to reduce lipid peroxidation more 
effectively than vitamin C or E (Gitto et al., 2001).  Lipid peroxidation is the process 
whereby lipids undergo oxidative degradation.  In this process, free radicals steal 
electrons from the phospholipids in the cell membrane and cause cell damage.  The 
antioxidant properties of melatonin in vivo are demonstrated by the ability of melatonin 
to reduce ischemia-reperfusion injury in various organs of rats, including the heart (Tan 
et al., 1998), kidney (Sahna et al., 2005), brain (Cho et al., 1997) and liver (Sewerynek et 
al., 1996).  Using the rat as a model, various experiments have been carried out in which 
pharmacological or physiological levels of melatonin have been used to protect the heart 
against ischemia-reperfusion (I/R) injury.  This refers to the tissue damage that is caused 
after the blood supply returns to a tissue that has experienced a period of oxygen 
deprivation.  In these studies, either exogenous melatonin was administered before, 
16 
 
during and after I/R injury to the heart, or the rats were pinealectomized to reduce 
endogenous levels of melatonin. The results showed a significant reduction in damage 
due to oxidative stress clearly owing to the concentration of melatonin.  It was shown 
that the presence of melatonin reduced premature ventricular contractions and 
ventricular fibrillation, reduced ventricular tachycardia, reduced lipid peroxidation and 
lowered OH radical generation, reduced reperfusion arrhythmias and infarct volume and 
lowered mortality (Paulis & Simko, 2007).  In addition to melatonin’s protective effects 
of cardiac tissue, its protective effects of other tissue types have also been researched.  In 
the in vivo brain (including the spinal cord), liver, kidney, gastrointestinal tract, lung and 
placenta, the amount of tissue damage and the severity of compromised function after 
I/R were shown to be reduced when melatonin was employed as an ameliorative agent.  
Furthermore, the damage inflicted by other agents that induce high oxidative stress is 
reduced when melatonin is exogenously administered (Paulis & Simko, 2007).   
 There is also evidence that melatonin’s cardio-protective effects may be receptor 
mediated.  In 2006, Rezanni et al., looked at the beneficial effects of melatonin in 
protecting against cyclosporine-A (CsA)-induced cardio-toxicity.  When melatonin and 
CsA were injected along with luzindole, a melatonin receptor antagonist, it showed that 
the protective effects of melatonin were lost when the animals received the melatonin 
receptor antagonist.  Melatonin’s cardio-protective effects against myocardial 
ischemia/reperfusion (MI/R) injury in rats was were blocked by luzindole in 
experiments performed by Yu et al., in 2014.   
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Luzindole also abolished the short and long term cardio-protective effects of melatonin 
administered both before, during and after induced myocardial ischemia in rats 
(Lochner, 2006).  Luzindole was also shown to block melatonin’s ability to reduce blood 
pressure by binding to ML1 receptors in the anterior hypothalamic area (AHA) of the rat 
brain (Ding et al., 2001). 
 There are several non-specific mechanisms of melatonin action as well, which 
are unrelated to its antioxidant properties.  Melatonin is thought to modulate the 
calcium/calmodulin signaling pathway either by changing intracellular Ca2+ 
concentration via activation of its G-protein–coupled membrane receptors, or through a 
direct interaction with calmodulin (CaM) (Turjanski et al., 2004).  CaM is known to 
interact with a large number of proteins important for Ca2+ -dependent intracellular 
signaling, thus enabling the cell to control biological processes as diverse as muscle 
contraction, fertilization, cell proliferation, vesicular fusion, and apoptosis (Berridge et 
al., 1998).  Satake et al., (1991) found that the inhibition of Ca2+ channels by melatonin 
causes vasorelaxation in the isolated rat aorta.  Chen et al., (1993) found that there are 
time-dependent changes in [Ca2+ + Mg2+]-dependent ATPase activity that are absent in 
pinealectomized or light-exposed rats, and that in-vitro studies of cardiac tissue 
incubated in the presence of melatonin over a wide range of doses showed that 
melatonin stimulated the Ca2+ pump. These findings suggest that the daily change in 
[Ca2+ + Mg2+]-dependent ATPase activity in the sarcolemma of heart tissue is a result of 
the circadian rhythm in pineal melatonin production and secretion. These findings may 
be applicable to understanding normal cardiac physiology. 
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Melatonin research with Drosophila 
  Some melatonin research has been done using Drosophila melanogaster as a 
model.  Arylalkylamine N-acetyltransferases (AANATs) are enzymes which catalyze 
the rate limiting step in melatonin synthesis in the vertebrate pineal gland.  More 
specifically, conversion of serotonin (5-hydroxytryptomine; 5-HT) to N-acetylserotonin, 
the precursor of the circadian neurohormone melatonin, is catalyzed by serotonin N-
acetyltransferase (AANAT) in a reaction requiring acetyl coenzyme A (AcCoA) 
(Hickman et al., 1999).  Two different AANATs (AANAT1 and AANAT2) have been 
identified and characterized in Drosophila melanogaster (Hintermann & Meyer, 1995; 
Brodbeck et al., 1998; Amherd et al., 2000).  A second enzyme, HIOMT, involved in O-
methylating N-acetylserotonin in the final step of the melatonin synthesis pathway, has 
not yet been discovered in Drosophila.   
 Four receptors for 5-HT have been described in Drosophila: one shares sequence 
homology to the vertebrate 5HT receptor type 2 (5HT2R; CG1056), one is similar to the 
vertebrate serotonin receptor type 7 (5HT7R; CG12073) and two show high homology to 
vertebrate 5HT1 type receptor (5HT1AR and 5HT1BR; CG16720 and CG15113, 
respectively) (Silva et al., 2014).  Computed gene (CG) numbers were used for genes 
identified during the annotation of the whole Drosophila genome sequence (Vaudry & 
Seong, 2014).  Drosophila melanogaster synthesizes its own serotonin (Livingstone, 
1981) and also has several clusters of serotonergic neurons located in its central nervous 
system (Valles, 1988). 
 Bonilla et al., (2006) found that melatonin was more effective than serotonin, 
lipoic acid and ascorbic acid at counteracting paraquat-induced oxidative stress in D. 
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melanogaster.  In another pesticide exposure study, flies exposed to rotenone exhibited 
the neurodegenerative and behavioral deficits classically seen in Parkinson’s disease 
(PD).  Melatonin introduced into the feeding medium alleviated both symptomatic 
impairment and neuronal loss, supporting the idea that this agent may be beneficial in 
the treatment of PD (Coulom & Birman, 2004).  In further examination of melatonin’s 
antioxidant properties, a wild-type strain of D. melanogaster was exposed to the catalase 
inhibitor 3-amino-1,2,4-triazole in an effort to enhance oxidative stress from endogenous 
sources.  While most of the flies that were fed inhibitor alone died, flies fed a 
combination of inhibitor and melatonin had a much higher survival rate (Coto-Montes 
and Hardeland, 1999).  In addition to its protective effects, several studies have shown 
that melatonin-fed flies have a significantly increased lifespan (Li & Xu, 1997; 
Izmaylov & Obukhova, 1999; Bonilla et al., 2002; Anisimov, 2003; Terán et al., 2012).   
 The mechanism by which melatonin exerts its effects in D. melanogaster is not 
known.  Because there had been no melatonin receptors identified in the fruit fly when I 
began my research, it was unclear whether melatonin acted only as a powerful 
antioxidant and free radical scavenger or had other, receptor-mediated effects that may 
be directly or indirectly regulating pacemaker activity.  I proposed to conduct a series of 
experiments that would allow me further to explore melatonin’s effects on pacemaker 
activity, emphasizing both genetics and pharmacology, and was eager to determine 
whether melatonin receptors are present in Drosophila melanogaster.  Based on 
preliminary research in our lab that showed melatonin’s effects on rhythmicity in wild-
type hearts (Powers, unpublished), prior research identifying melatonin receptors and the 
effects of melatonin in various organ systems of human and other mammalian models, 
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and known homologies between the Drosophila and human genomes, I hypothesized 
that Drosophila melanogaster does have at least one melatonin receptor and that 
pacemaker activity is modulated by melatonin at the receptor level.  If pacemaker 
activity is in fact modulated by melatonin at the receptor level in Drosophila, this will 
give us more clues about the mechanisms of melatonin’s action in improving and 
protecting the human cardiovascular system. 
Overview of research objectives 
 There has been no reported research to date that examines the antioxidant or other 
effects of melatonin on heart function in Drosophila melanogaster.  An Honor’s student 
in our lab carried out a series of experiments where wild-type Drosophila pupae were 
injected with varying concentrations of melatonin.  Heart rate and rhythmicity were 
recorded and compared before and after injection.  Results of these experiments showed 
no change in heart rate, but a significant increase in rhythmicity in previously 
arrhythmic hearts (Powers, unpublished).  Although these results were not reported, they 
sparked my interest as to the mechanisms behind the rhythmicity increase.   
 The goals of my dissertation research have been twofold: 1. to examine the effects of 
melatonin on heart rhythmicity and frequency in various strains of Drosophila 
melanogaster, both wild-type and those bearing mutations affecting cardiac function.    
2. to identify a melatonin receptor in Drosophila melanogaster and, therefore, elucidate 
whether melatonin’s action is antioxidant related or receptor mediated.  I believe that by 
combining genetics and pharmacology, the mechanism of melatonin action can be better 
understood. 
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Effects of melatonin on heart rate and rhythmicity 
 In chapter 1, I examined the response of Canton S (CS) (Drosophila 
melanogaster wild- type flies) to injections of varying concentrations of melatonin (0, 
50 µM, 100 µM, 500 µM, 1000 µM and 2500 µM).  With these data, I constructed a 
dose-response curve that allowed me to determine the most effective concentration of 
melatonin to use in subsequent experiments (1000 µM).   Once this was determined, I 
injected the optimal concentration of melatonin into various strains of Drosophila that 
have a variety of different heart mutations, looking for a possible “rhythmicity rescue” 
of the mutation by melatonin.  Since these mutations cause genetically-based alterations 
of heart physiology (usually pacemaker ion channels), rescuing an effect of a mutation 
with melatonin strongly implicates receptor-mediated activity of melatonin.   
 The mutations I tested were no action potential temperature sensitive (napts),                                
Ca-P60A Kumbhakarna 170 (SERCA170), slowpoke (slo), dunce (dnc1) and ether-a-go-go 
(eag).  These particular heart mutations involve variations either in ion channel activity 
or in intracellular calcium concentrations of the Drosophila pacemaker.   
After my initial testing of the Drosophila mutant slo, I compared a dose response 
in this animal to that of CS wild-type flies by injecting slo pupae with the same 
concentrations of melatonin as described above (0, 50 µM, 100 µM, 500 µM, 1000 µM 
and 2500 µM). 
 The next set of experiments involved crossing the slo mutant with the df [slo] 
(slowpoke deficiency) strain.  Deficiency stocks comprise chromosomal deletions which 
provide definitive null alleles for the genes they uncover on the sister chromosome and 
22 
 
are used to gauge the severity of any particular allele; indeed, the classical test for 
defining an amorphic or null allele is to assess whether the homozygous phenotype is as 
severe as when the allele is hemizygous with a deletion (Roote and Russell 2012).  First 
generation (F1) progeny of this stock were injected with the optimal concentration of 
melatonin and the resulting rhythmicity index and frequency were analyzed. 
  My final set of experiments compared the effects serotonin, melatonin’s 
precursor, with the effects of melatonin on heart rate and rhythmicity.  Previous 
experiments carried out by Johnson et al.,1997, showed that serotonin significantly 
increased heart rate without increasing heart rhythmicity.  Serotonin exerts its positive 
chronotropic effects by binding to 5-HT2 receptors that have been identified in the larval 
heart and aorta of Drosophila melanogaster (Majeed et al., 2014). 
Melatonin receptor identification  
  The experiments described in the chapter 2 consist of a combination of 
pharmacological and genetic techniques designed to identify a possible melatonin 
receptor in Drosophila melanogaster and, therefore, determine whether melatonin’s 
effects on heart rhythmicity are antioxidant related or receptor mediated. 
Pharmacological experiments 
  Receptor identification often involves administration of known antagonists or 
agonists to the ligand in question.  If melatonin is increasing heart rhythmicity in 
Drosophila by binding to a receptor, an antagonist acting at the receptor level, such as 
luzindole, will block these effects.  Similarly, injection of a melatonin receptor agonist, 
such as 2-iodomelatonin, may mimic melatonin’s effects. 
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 The first set of experiments involved double injections of melatonin and 
luzindole   in Canton-S, slowpoke and napts Drosophila pupae.  Injection Protocol: first 
inject pupa with 2500 µM luzindole, allow to rest for 1.5 minutes, then inject pupa with 
1000 µM melatonin and immediately begin heart recording lasting for 10 minutes. 
 The second set of experiments involved injection of 1000 µM 2-iodomelatonin 
only in Canton-S and slowpoke pupae.  Injection Protocol: an initial 10 minute pre-
injection heart recording is followed by injection, then a 10 minute post-injection heart 
recording. 
My final set of pharmacological experiments involved the injection of another 
known powerful antioxidant, ascorbic acid (vitamin C) in order to investigate further the 
mechanism of melatonin’s effects on heart rhythmicity.  Melatonin is a very powerful 
antioxidant that was found to be more effective than vitamin C or vitamin E in 
combating paraquat induced oxidative stress in Drosophila melanogaster (Bonilla et al., 
2006).    Canton-S (wild-type) and slowpoke (mutant) flies were injected with the 1000 
µM ascorbic acid which was also dissolved in calcium free ringers with 1% ETOH.  
Heart rhythmicity index and frequency results were then compared to those of Canton-S 
and slo flies that were injected with calcium-ringers with 1% ETOH (controls).  2-
iodomelatonin and melatonin. 
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RNAi Experiments 
 Ribonucleic Acid Interference (RNAi) is a process that permits elimination of 
expression of targeted gene sequences in an attempt to understand their function (Bellés, 
2010).  RNAi strains of orphan G-protein coupled receptors were crossed with a GMH5 
driver that effectively silenced the gene in question in cardiac tissue.  I chose four 
Drosophila orphan GPCRs to test: CG4313, CG3171, CG13579, CG13575.  These 
specific strains were chosen because they come from a structural class of GPCRs that 
are known to bind substances that are structurally similar to melatonin.   
 
Figure I.1: The Generation of RNAi from dsRNA is completed as follows (a) the 
experimentally derived dsRNA binds to the enzyme dicer which cleaves the dsRNA at 
targeted sites (b). The coupling of a RISC to target mRNA creates cleavage (c) small 
subunits of mRNA (d) that are able to effectively silence targeted genes (Bellés, 2010). 
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CHAPTER 1 
THE EFFECTS OF MELATONIN ON Drosophila HEART RATE AND 
RHYTHMICITY 
Abstract 
Melatonin (N-acetyl-5-methoxytryptamine), has been shown to have both cardio- 
protective and anti-arrhythmic properties in vertebrates largely owing to its powerful 
antioxidant properties.  Very few studies have attributed improvements in cardiovascular 
health to the binding of melatonin to its receptors (MT1 and MT2).  In the present study, 
micro molar concentrations of melatonin injected into the P1 pupae of Drosophila 
melanogaster wild type and the following heart mutants (slo, dnc1, eag, naptsand Ca-
P60AKum170) show acute and profoundly significant increases in heart rhythmicity across 
all subjects ranging from 54-104 % without significantly affecting heart rate of these 
animals.  Effects of melatonin were also compared to injections of the melatonin 
precursor serotonin (5-hydroxytryptamine), where serotonin significantly increases heart 
rate in wild type and slo without significantly increasing heart rhythmicity.  In 
conclusion, the acute antiarrhythmic effects of melatonin injection in Drosophila 
melanogaster are likely receptor-mediated based on the combination of collective data 
from the experiments performed in Chapters 1 & 2. 
Introduction 
There are a variety of causes of cardiovascular disease ranging from inherited 
conditions that alter heart structure or cause dysfunction in pacemaker ion channels, to 
ischemic cardiac events that result in damage to heart tissue from oxidative stress and 
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subsequent remodeling of heart structures.  Furthermore, these diseases, whether 
inherited or acquired, are associated with different types of heart arrhythmias that alter 
overall function of the heart and often lead to sudden cardiac death.  Clinical and 
pathologic findings suggest that patients with conditions such as coronary artery disease, 
cardiomyopathy, cardiac rhythm disturbances, or hypertensive heart disease are at high 
risk of SCD (Roberts, 1990).  Abnormal heart rhythms, notably atrial and ventricular 
fibrillation, are leading causes of death and disability. Between 0.5 million and 1 million 
North Americans and Europeans die each year from sudden cardiac death (SCD), which 
causes 10–20% of all deaths among adults in the Western world (De Vreede-
Swagemakers et al., 1997; Zheng et al., 2001).  Prevention and treatment of cardiac 
arrhythmias include medical procedures such as cardioversion, implantable cardioverter 
defibrillators (ICDs) and catheter ablation; surgical procedures such as coronary artery 
bypass grafting; and the use of anti-arrhythmic medications.  While some procedures 
like radio-frequency ablation can cure arrhythmias (Morady, 1999), available anti-
arrhythmic drugs are incompletely effective in preventing arrhythmias, and such 
treatment carries risks, including actually promoting arrhythmia (Knollmann & Roden, 
2008).  An understanding of the underlying mechanisms of arrhythmias is essential to 
the future development of safe and effective preventative therapies. 
The study of heart development and physiology in Drosophila melanogaster is 
intensifying rapidly as it continues to expand as a model system for studying cardiac 
problems generally and genetic influences in particular.  Findings in the fly are directly 
applicable to the human heart as a growing number of genes have been identified with 
homologous function in both organisms (Bier & Bodmer, 2004).   Drosophila 
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melanogaster is the only insect in which the molecular genetic basis of heart 
development process has been studied and reviewed in detail.   Drosophila has an open 
circulatory system consisting of a simple, linear, tubular heart that circulates hemolymph 
through the larval and adult body cavity (Rizki, 1978).  The transport of oxygen in the 
fruit fly is carried out by their highly branched tracheal system.  In stark contrast, the 
vertebrate heart consists of an elaborate, closed system of chambers and vessels that 
transport blood through the body of the organism in order to provide oxygen to the 
tissues.  Although the final heart structure in Drosophila is very different from that of 
vertebrates, many of the basic elements for cardiac specification and differentiation are 
conserved.  The molecular components and basic control mechanisms of how the heart 
develops and how it functions are strikingly similar in vertebrates, other chordates, and 
insects (Bodmer, 1995; Bodmer & Venkatesh, 1998; Cripps & Olson, 2002; Harvey, 
1996; Holland et al., 2003; Zaffran & Frasch, 2002).    (See Section I Introduction for 
more detail about Drosophila melanogaster heart development.)   
Melatonin (N-acetyl-5-methoxytryptamine), the main product of the pineal 
gland, is well known for its regulation of the biorhythms.  Since the identification of 
melatonin by Lerner et al. (1958), it has been shown that melatonin is involved in the 
regulation of many physiological systems, including the cardiovascular system (Vazan 
et al., 2003;2005).  Melatonin effects its response by either binding to one of its three 
receptors (MT1, MT2 or MT3), binding to nuclear receptors, or through its antioxidant 
activity.  Very little research has been done attesting to melatonin’s effects on heart 
arrhythmias.  Only two studies have shown a relationship between melatonin and 
reduced heart arrhythmia in rats (Bertuglia & Reiter, 2007; Benova et al., 2015).   The 
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former attributed melatonin’s anti-arrhythmic effects to its acute effects on myocardial 
Cx43 channel’s mediated electrical coupling via Cx43 phosphorylation; the latter 
attributed melatonin’s anti-arrhythmic effects to its ability to prevent tissue damage after 
ischemia-reperfusion injury due to its powerful antioxidant activity.  (See Section I 
Introduction for more detail on melatonin.) 
In this study, I examined the effects of melatonin and serotonin on heart rate 
(frequency) and rhythmicity of Drosophila melanogaster wild-type and heart mutants 
when injected into early (P1) pupae.  If melatonin is exerting its anti-arrhythmic effects 
via antioxidant mediated activity, it is expected that injection with serotonin will 
produce similar results, owing to its equally powerful antioxidant properties.  The 
selected heart mutants (slowpoke, ether-a-go-go, no action potentialtemperature sensitive, 
dunce, sarco-endoplasmic reticulum Ca2+-ATPase allele 170) were chosen based on 
their arrhythmic phenotypes.  (See Section I Introduction for a more detailed description 
of the aforementioned Drosophila mutants.) 
Based on a smaller scale study previously performed in our lab, I predicted 
melatonin would increase heart rhythmicity without altering heart rate in Drosophila 
wild type flies and some Drosophila heart mutants.  The following experiments were an 
attempt to elucidate the mechanism by which melatonin might be exerting its anti-
arrhythmic effects by observing the responses of the different heart mutants.  Previous 
experiments with Drosophila melanogaster have shown the acceleratory effects of 
injected neurotransmitters such as serotonin, octopamine, norepinephrine, and 
acetylcholine (Johnson et al., 1997), but there have been no published or reported 
experiments carried out with melatonin thus far. 
29 
 
Materials and Methods 
Fly Cultures and Strains 
All mutant and control strains were maintained in 250ml bottles in a 12:12 light: 
dark (L:D) cycle under uncrowded conditions in a humidified, temperature-controlled 
incubator at 25º on malt-molasses-cornmeal-agar medium.  No population bottlenecks 
occurred.  Propionic acid was added to the medium to control mold growth (Jennings et 
al. 2009).   
Genetics 
Homozygous individuals of the following Drosophila melanogaster strains were tested: 
Canton-S (CS) wild-type 
dunce (dnc1) (Dudai et al., 1976)  
ether-a-go-go (eag) (Wu et al., 1983; Drysdale et al., 1991; Brüggemann et al., 1993) 
no action potential temperature sensitive (napts) (Wu et al., 1978) 
sarco-endoplasmic reticulum Ca2+-ATPase allele 170 (Ca-P60AKum170)  
(Sanyal et al., 2005)  
slowpoke  (slo) (Elkins et al. 1986) 
 
Reciprocal crosses were carried out with the mutant strain slowpoke and df [slo] 
(slowpoke deficiency).  Crosses with deficiency stocks lead to deletions which provide 
definitive null alleles for the genes they uncover and are used to gauge the severity of 
any particular allele; indeed, the classical test for defining an amorphic or null allele is to 
assess whether the homozygous phenotype is as severe as when the allele is hemizygous 
with a deletion (Roote & Russell, 2012).  One cross contained 10 slowpoke virgin 
females and 10 df [slo] males.  The second cross contained 10 df [slo] virgin females and 
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10 slowpoke males.  Reciprocal crosses were maintained in 250ml bottles under the 
same environmental conditions described above. 
 Ribonucleic Acid Interference (RNAi) is a process that permits elimination of 
expression of targeted gene sequences in an attempt to understand their function (Bellés 
2010). Ten slo RNAi virgin females were crossed with 10 GMH5-Gal4 males in order 
to eliminate slo and mimic the slo mutation phenotype.  This cross was maintained in a 
250 ml bottle under the same environmental conditions described above. The heart-
specific driver employed here is GMH5–Gal4, a 900-bp heart enhancer fragment 73 
from the tinman gene (Bodmer, 1993; Venkatesh et al., 2000) that was cloned into the 
P{GaWB} vector upstream of the Gal4 sequences. This driver was enhanced with 
multiple copies of a UAS–Gal4 element allowing stronger myocardial expression when 
activated in late embryonic or during adult stages (Wessells & Bodmer, 2004). 
Measurement of Heartbeat 
All test subjects were collected at the third-instar larval stage just as they were 
entering the early pupal (P1) stage.  At this point, they are translucent, making any heart 
movements transmitted to the surrounding organs easily visible.   Each pupa was placed 
on a glass slide in a drop of distilled water and set in the light beam of an Olympus 
binocular microscope.  The light source was powered by a DC supply to eliminate 60 Hz 
variation.  The water served to stabilize and equilibrate temperature between the slide 
and the pupa, as well as to increase the brilliance of the illumination passing through the 
pupa.  The pupa was adjusted so that one clear portion of the abdomen filled the field of 
view with just the surrounding fat bodies visible.  The movement of these organs results 
in a variation in illumination that can be detected by a phototransistor.  This signal is 
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amplified and recorded in a microcomputer through a DAS8 AD converter (Johnson et 
al., 1997).  Temperature of the slide was maintained at 25 ̊ C with a Sensortek TS-4 unit, 
however it was not possible to record temperatures within the animals.   Recordings 
were done for 10 minutes pre-injection and again post-injection.  Over the 10-minute 
time period for both pre-and post-injection recordings, heart frequency and heart 
rhythmicity data were recorded at 1-minute intervals, resulting in 10 separate readings.  
This allowed for analysis of the effects of injected substances over time.  For pre-
injection recordings each pupa was allowed 1.5 minutes to equilibrate to 25 ̊ C after 
being placed under the microscope and before recording started.  After injection of a 
substance, flies were immediately placed under the microscope and recording was 
started without the 1.5 minute equilibration time in order to observe the immediate 
effects of the injected substance. 
Test of Ca-P60AKum170 mutant strain specifics 
   Both pre and post injection heartbeat were recorded for 10 minutes at 25 ̊ C for 
the Ca-P60AKum170 mutant strains.  In addition to the protocol for the other subjects, Ca-
P60AKum170 mutants were also exposed to a 2.5 minute heat shock at 41 ̊ C either before 
or after melatonin injection; in between pre- and post-injection heartbeat recordings. 
For pre-injection heat shock, each pupa was placed in a glass vial and then 
submerged in a 41 ̊ C water bath for 2.5 minutes.  The pupa was then immediately 
transferred to a glass slide, injected with melatonin and placed under the microscope for 
post-injection recording.  For post-injection heat shock, each pupa was first injected, 
then immediately placed in a glass vial and subjected to the 41 ̊ C water bath for 2.5 
minutes.  The pupa was subsequently transferred to a glass slide and immediately placed 
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under the microscope for post injection recording.  Post-injection pupae were not 
allowed any time to acclimate before recording to allow observation of any immediate 
effects that injected substances might have. 
Pharmacology of melatonin and ascorbic acid 
Melatonin is insoluble in water and must initially be dissolved in ethyl alcohol.  
For consistency, both melatonin and ascorbic acid were first dissolved in 1 % ethyl 
alcohol and then added to Calcium-free Drosophila Ringer’s solution (Ashburner, 
1989).  Concentrations of 2500 µM, 1000 µM, 500 µM, 100 µM, and 50 µM melatonin 
were prepared to assay dose response. A single concentration of 1000 µM ascorbic acid 
was prepared.  Based on these results, the standard concentration used for ensuing 
experiments of both melatonin and ascorbic acid injections was 1000 µM.  
Solutions were perfused directly over the pacemaker and caudal region of the 
dorsal vessel by injection into the caudal end of the animal (Johnson et al., 1997).  Glass 
electrodes were used for injection and were pulled on a World Precision Instrument 
PUL-100 micropipette puller.  Tips were gently broken to assure sharpness. 
Following a 10 minute pre injection recording, the pupa was placed under an 
Olympus dissecting scope for injection.  A World Precision Instrument Nanoliter 
Injector (model # A203XVY) was calibrated to administer 46 nl volume of liquid.  A 
micromanipulator was used to position the glass electrode in the dorsal posterior region 
near the caudal region of the heart.  Heartbeat was recorded for 10 minutes before 
injection and for 10 minutes immediately (within 1 minute) after injection of a substance 
as delineated above. 
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Analysis of heartbeat data 
Data from individual flies taken at 25 ̊ C were analyzed by autocorrelation 
(Chatfield, 1980) and Maximum Entropy Spectral Analysis (MESA) (Ulrych & Bishop, 
1975; Dowse, 1989; Levine et al., 2002; Dowse, 2009).  Estimations of heart rate 
frequency were based both on the spectral analysis and on inspection of the raw data 
plots and autocorrelation for verification.   
Regularity of the heartbeat was quantified from the autocorrelation analyses.  
Rhythmicity in the signal results in recurring peaks of positive and negative correlation 
and the decay envelope reflects regularity in the signal (Chatfield, 1980).  The height of 
the second peak was expressed as a fraction of the height of the zeroth lag, (i.e., a 
coefficient of correlation; see Dowse et al., 1995; Levine et al., 2002; Dowse, 2009 for 
details).  We refer to this coefficient as “rhythmicity (RI).”  We commonly observe that 
with more skipped beats, irregular intervals between beats, periods of heartbeat 
cessation, and rate variations tracks the level of irregularity in RI (Johnson, Ringo, & 
Dowse, 2000; Levine et al., 2002; Dowse, 2009). 
The program was set up to measure heart rate frequency and heart rhythmicity 
over a 10 minute period.  At each minute over the 10 minute period, a value for 
frequency and rhythmicity was calculated.  This program allows us to examine the 
effects of injected substances over a longer period of time allowing estimates of when 
the effects began and how long they last (see figure 1.1). 
In order to further explore the way in which the heartbeat was altered by the 
injection of melatonin, we wrote software to sort through the recorded data to pinpoint 
and record the duration of the interval between each peak in the signal and the next.  
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Intervals in which the signal equaled or exceeded the mean of the absolute value of the 
time series were identified sequentially and a simple bubble sort was applied to identify 
the highest value in this time frame.  Its time was recorded.  Thus we are able to 
visualize the “Inter-Beat Interval” or IBI as a function of time.  Fig 1.1g-j shows an 
example of this analysis, the IBI for a Canton-S pupa recorded for 10 minutes and 
plotted as a function of time. 
Because each fly was used as its own control and more than two measurements 
were carried out on the same subject Repeated Measures Analysis of Variance 
(ANOVA) tests were used to compare data before injection and after injection for each 
Drosophila strain tested.   Kolmogorov-Smirnov goodness of fit tests were used to show 
that all data were normally distributed.  Both tests were carried out within the statistical 
software R.  
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Results 
Data Analysis Figures 
Figure 1.1  Full analysis of the heartbeat of a CS pupa before and after injection 
with 1000μM melatonin. a, b Raw data optical recording: a 30-s segment starting at the 
midpoint of the raw data before (a) and after (b) melatonin injection shows this 
difference in more detail.  This 30-s segment is representative of the 4 minute segments 
indicated in (k).  c, d Autocorrelation for these segments used to assess regularity of 
heart rhythm before (c) and after (d) melatonin injection.  e, f Spectral analysis (MESA) 
for heart rate (frequency) of these segments starting at the midpoint before (e) and after 
(f) melatonin injection.  g, h  Interbeat Interval (IBI) analysis shows this change in a 
more objective fashion.  (g) (before) and (h) (after) show the IBI analyses for both 
records in their entirety.  The change in regularity is easily seen after a period of “wash 
in”.  Note the development of the more regular beat after the wash-in period.  i, j 30-s 
segments starting at the midpoint of the data show the IBI analysis at higher 
magnification before (i) and after (j) injection.  The difference in the variability of IBI is 
striking.  Autocorrelation and MESA for these segments (c) and (d) and (e) and (f) are 
remarkable and clearly track the change in IBI.  Together, these analyses point towards 
the increase in RI stemming from the change in variance in IBI. (k) Shows the average 
(CS pupae, N=30) rhythmicity index (RI) for each minute; 10 minutes before injection 
and 10 minutes after injection.  The horizontal bar over minutes 4-7 and 15-18 indicate 
time segments used for comparison in all experiments. 
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a. Raw data optical recording: a 30-s segment starting at the midpoint of the raw data 
before melatonin injection 
 
b.   Raw data optical recording: a 30-s segment starting at the midpoint of the raw data 
after melatonin injection 
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c.   Autocorrelation used to assess regularity of heart rhythmn before melatonin injection 
 
d.  Autocorrelation used to assess regularity of heart rhythmn after melatonin injection 
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e.  Spectral analysis (MESA) for heart rate (frequency) of these segments starting at the 
midpoint before melatonin injection 
 
f.  Spectral analysis (MESA) for heart rate (frequency) of these segments starting at the 
midpoint after melatonin injection 
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g.  Interbeat Interval (IBI) analysis of entire 10 minute recording before melatonin 
injection 
 
h.  Interbeat Interval (IBI) analysis of entire 10 minute recording after melatonin 
injection 
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i. IBI analysis at higher magnification; 30-s segment starting at the midpoint before 
melatonin injection 
 
j.  IBI analysis at higher magnification; 30-s segment starting at the midpoint before 
melatonin injection 
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k.  Shows the average (CS pupae, N=30) rhythmicity index (RI) for each minute; 10 
minutes before injection and 10 minutes after injection 
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Dose response of injected melatonin in wild type and slowpoke pupae 
 Both wild type and slowpoke pupae were injected with 50, 100, 500, 1000 and 
2500 µM concentrations of melatonin.  Wild-type (Canton-S) pupae showed significant 
increase in heart rhythmicity with injections of 500, 1000 and 2500 µM melatonin with 
% increase in heart rhythmicity of 32 %, 47 % and 39% respectively (p < 0.05) as 
compared to rhythmicity before melatonin injection.  Melatonin injections of 0 µM 
(control injections of Ca+2 free ringers and Ca+2 free ringers with 1% ethanol), 50 µM 
and 100 µM in wild type pupae showed no significant change in heart rhythmicity        
(p > 0.05) (Figure 1.2).  Slowpoke (slo) pupae showed significant increase in heart 
rhythmicity with injections of 100, 500, 1000 and 2500 µM melatonin with  
%  increase in heart rhythmicity of 19 %, 77%, 98% and 40% respectively (p < 0.05).  
Melatonin injections of 0 µM (control injections of Ca+2 free ringers and Ca+2 free 
ringers with 1% ethanol), and 50 µM slo pupae showed no significant change in heart 
rhythmicity (p > 0.05) (Figure 1.3).  There was no significant change in heart rate in 
either wild type or slo pupae across all injected concentrations of melatonin (p > 0.05).  
The peak response for both wild type and slo pupae was with injection of 1000 µM 
melatonin.  This was chosen as the standard dose used in all experiments. 
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Figure 1.2  Canton-S melatonin dose response curve 
 
Figure 1.3  Slowpoke melatonin dose response curve 
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Effects of melatonin on heart rate and rhythmicity of Drosophila melanogaster 
wild- type and heart mutant pupae 
 Both wild type and heart mutant pupae injected with 1000 µM melatonin showed 
significant increase in heart rhythmicity ranging from 54 to 104% (Table 1.1 and Fig 
1.4).  Canton S, eag, slo, napts, and slo x  df [slo]d pupae showed a significant decrease 
in heart rate ranging from 2 to 12 %  (p < .05), but all other strains showed no significant 
change in heart rate (Table 1.2 and Fig. 1.5). 
 Control pupae were injected with Drosophila calcium free ringers solution or 
calcium free ringers solution with 1% ethanol.  Controls showed no significant change in 
heart rhythmicity or in heart rate (p > 0.05).   
 Due to the initial period of time that it took for melatonin to exert its effects, 
minutes 4 through 7 were chosen as significant values for calculation of the means taken 
pre and post injection for both heart rate and rhythmicity.  This protocol was used across 
all measurements except those involving a heat shock protocol (see fig. 1.1k). 
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Table 1.1  Effects of melatonin injection on heart rhythmicity in wild-type and heart mutants 
      
 
   Genotype 
   Meltonin         
Injected 
   µmol-1a 
 
Mean 
RI 
Preb 
25´C 
Mean
RI 
Postc 
25´C 
     
% 
Change 
 
         
N 
 
   
 +/- SEM 
Pre/Post 
   
  
  F Value 
      
 
    P Value 
Canton-S (+) 1000 0.449 
 
0.694 
 
+54% 30 0.02/0.02 (1,29) 158.7 <2e-16 *** 
dnc1 1000 0.404 
 
0.702 
 
+74% 10 0.04/0.04 (1,9) 86.4 2.00e-13 *** 
eag 1000 0.287 
 
0.584 
 
+104% 5 0.04/0.04 (1,4) 120.7 1.16e-11 *** 
napts 1000 0.406 
 
0.746 
 
+84% 30 0.02/0.01 (1,29) 338.6 < 2e-16 *** 
slo 1000 0.357 
 
0.681 
 
+91% 42 0.02/0.01 (1,41) 61.4 9.29e-14 *** 
slo x df [slo] d 1000 0.418 
 
0.733 
 
+76% 20 0.02/0.02 (1,19) 341.6 < 2e-16 *** 
 df [slo] x sloe 1000 0.379 
 
0.711 
 
+87% 11 0.02/0.02 (1,10) 292.1 <2e-16 *** 
sloRNAi x GMH5f 1000 0.305 
 
0.570 
 
+87% 5 0.03/0.02 (1,4) 86.1 4.89e-10 *** 
 
aConcentration of melatonin injected 
bMean Rhythmicity Index pre-injection minutes 4-7 
cMean Rhythmicity Index post-injection minutes 4-7 
dslo virgin females crossed with df [slo] males 
edf [slo] virgin females crossed with slo males 
fsloRNAi virgin females crossed with GMH5-Gal4 males 
*** p < 0.001 comparing before injection to after melatonin injection within each strain 
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Figure 1.4  Effects of 1000 µM melatonin injection on wild-type and heart mutants 
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Table 1.2  Effects of melatonin injection on heart rate in wild-type and heart mutants 
    
 
  Genotype 
   Meltonin         
Injected 
   µmol-1a 
 
Mean 
Heart 
Rate 
Preb 
25´C 
Mean 
Heart 
Rate 
Postc 
25´C 
   
      % 
 Change 
 
    
   N 
 
     
+/-SEM 
Pre/Post 
    
 
F  Value 
     
 
    P Value 
Canton-S  (+) 1000 2.28 
 
2.21 
 
- 3 % 30 0.02/0.03 (1,29) 6.1 0.0144 * 
dnc1 1000 2.04 
 
1.98 
 
- 3% 10 0.03/0.04 (1,9) 1.3 0.251 
eag 1000 1.89 
 
1.80 
 
- 5% 5 0.03/0.04 (1,4) 5.4 0.027 * 
napts 1000 2.29 
 
2.01 
 
- 12% 30 0.05/0.05 (1,29) 19.1 4.69e-05 *** 
slo 1000 2.37 
 
2.28 
 
- 4% 42 0.02/0.02 (1,41) 14.7 0.00015 *** 
slo x  df [slo]d 1000 2.46 
 
2.41 
 
- 2% 20 0.04/0.04 (1,19) 5.7 0.0199 * 
 df [slo] x sloe 1000 2.16 
 
2.12 
 
- 2% 11 0.05/0.04 (1,10) 0.4 0.514 
sloRNAi x 
GMH5f 
1000 1.81 
 
1.72 
 
- 5% 5 0.05/0.04 (1,4) 2.3 0.140 
 
aConcentration of melatonin injected 
bMean heart rate pre-injection minutes 4-7 
cMean heart rate post-injection minutes 4-7 
dslo virgin females crossed with df [slo] males 
e df [slo]  virgin females crossed with slo males 
fsloRNAi virgin females crossed with GMH5-Gal4 males 
* p < 0.05 comparing before injection to after melatonin injection within each strain 
*** p < 0.001 comparing before injection to after melatonin injection within each strain 
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Figure 1.5  Effects of melatonin injection on heart rate in wild-type and heart mutants 
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Effects of melatonin injection on heart rhythmicity of Ca-P60AKum170 (SERCA 170) 
mutants before and after 2.5 minute heat shock at 41 ̊ C 
 Both wild-type and SERCA170 pupae showed a significant decrease in heart 
rhythmicity with 2.5 minute 41 ̊ C  heat shock alone  (F(1,4) = 153.6; p < 0.001 and 
F(1,4) = 32.6;    p < 0.001).  Injections of 1000 µM melatonin before and after heat 
shock showed significant increase in heart rhythmicity in both wild-type and SERCA170 
strains (Melatonin injection before heat shock: F(1,4) = 9.4; p < 0.05 and F(1,9) = 51.1; 
p < 0.001;  Melatonin injection after heat shock: F(1,4) = 30.1; p < 0.001 and F(1,9) = 
28.0; p < 0.001). (Fig. 1.6 and 1.7). 
 For recording where melatonin was injection before the 2.5 minute heat shock, 
minutes 1-10 of pre and post injection were compared and statistically analyzed.  For 
recordings where melatonin was injected after the 2.5 minute heat shock, minutes 7-10 
of pre and post injection were compared and statistically analyzed. 
 Comparison of wild-type to SERCA 170 mutants showed a similar trend where 
significant increase in heart rhythmicity occurred across the entire 10 minute recording 
with melatonin injection before heat shock, while significant increase in heart 
rhythmicity didn’t begin until minute 7 with melatonin injections after heat shock, and 
continued to increase from that point  (Fig. 1.8 and 1.9). 
 Control pupae were injected with Drosophila calcium free ringers solution with 
1% ethanol.  Controls showed no significant change in heart rhythmicity with injection 
before or after 2.5 minute heat shock at 41 ̊ C (p > 0.05).   
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Figure 1.6  Effects of 1000 µM melatonin injection on SERCA 170 pupae before and 
after 2.5 minute heat shock 
 
Figure 1.7  Effects of 1000 µM melatonin injection on Canton-S pupae before and after 
2.5 minute heat shock 
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Figure 1.8  Canton-S vs. SERCA 170  1000 µM melatonin injection after 2.5 minute heat 
shock 
 
Figure 1.9  Canton-S vs. SERCA 170 1000 µM melatonin injection before 2.5 minute 
heat shock 
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Effects of Serotonin on heart rate and rhythmicity of wild type and slowpoke 
mutants 
 Injection of 1000 µM serotonin in both wild-type and slowpoke pupae had no 
significant effect on heart rhythmicity (p > 0.05) (Table 1.9 and Fig 1.10). 
 Injections of 1000 µM serotonin did significantly increase heart rate in both 
wild-type and slowpoke pupae ranging from 28 to 31 %  (p < 0.001) (Table 1.10 and Fig 
1.11). 
 Results of serotonin injection are opposite of results of melatonin injection 
whereby melatonin increases heart rhythmicity without increasing heart rate, serotonin 
increases heart rate without increasing heart rhythmicity. 
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Table 1.3  Effects of 1000 µM serotonin injection on heart rhythmicity in wild-type and 
slowpoke pupae 
 
 
Genotype 
  Serotonin         
Injected 
   µmol-1a 
 
Mean 
RI 
Pre 
25´C 
Mean  
RI 
Post 
25´C 
      
     % 
 Change 
 
  
 N 
       
              
+/-   SEM 
Pre/Post 
 
 
F Value 
 
 
P Value 
Canton-S 
(+) 
1000 0.543 
 
0.585 
 
+7% 5 0.04/0.03 (1,4) 2.2 0.150 
slowpoke 1000 0.190 
 
0.211 
 
+11% 5 0.03/0.03 (1,4) 0.2 0.671 
 
aConcentration of serotonin injected 
bMean Rhythmicity Index pre-injection minutes 4-7 
cMean Rhythmicity Index post-injection minutes 4-7 
 
 
 
Figure 1.10  Effects of 1000 µM serotonin injection on heart rhythmicity in wild-type 
and slowpoke pupae 
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Table 1.4  Effects of 1000 µM serotonin injection on heart rate in wild-type and 
slowpoke pupae 
 
 
Genotype 
  Serotonin         
Injected 
   µmol-1a 
 
Mean 
Heart 
Rate 
Pre 
25´C 
Mean
Heart 
Rate 
Post 
25´C 
          
     % 
  Change 
 
      
 
N 
 
 
   +/-SEM 
Pre/Post 
 
 
   F Value 
 
 
    P Value 
Canton-S 
(+) 
1000 2.37 
 
3.11 
 
+ 31% 5 0.06/0.05 (1,4) 35.7 1.98e-06 *** 
slowpoke 1000 2.27 
 
 
2.91 
 
+ 28% 5 0.04/0.04 (1,4) 473.1 < 2.2e-16 *** 
 
aConcentration of serotonin injected 
bMean heart rate pre-injection minutes 4-7 
cMean heart rate minutes 4-7 
*** p < 0.001 comparing before injection to after serotonin injection within each strain 
 
 
Figure 1.11  Effects of 1000 µM serotonin injection on heart rate in wild-type and 
slowpoke pupae 
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Discussion 
 Heart rhythmicity in Drosophila melanogaster is remarkably and consistently 
increased by injection of melatonin in wild type pupae (P1) and pupae exhibiting a 
variety of heart mutations.  Percentage increase in heart rhythmicity ranged from 54% in 
wild-type to 104% in eag progeny.  Curiously, melatonin significantly increased heart 
rate by 7% in eag, but did result in a significant decrease in heart rate in Canton S, slo, 
eag, napts, and slo x df [slo]d pupae.  Data from injections with serotonin, melatonin’s 
precursor, also supported the previous findings of Johnson et al., 1997, that serotonin 
significantly increases heart rate in wild-type and slo pupae by 31% and 28% 
respectively without significantly affecting heart rhythmicity. 
 Both melatonin and serotonin exhibit powerful antioxidant properties owing to 
their ability to scavenge damaging free radicals produced by reactive oxygen species 
(ROSs) (Bonilla et al., 2006; Gülçin, 2008; Oxenkrug, 2005; Gitto et al., 2001; Head, 
2005; Pieri et al., 1994).  Serotonin was found to have higher DMPD (N, N–dimethyl-p-
phenylendiamine) radical scavenging and cupric ions (Cu2+) reducing activity than 
melatonin because of its phenolic group (Gülçin, 2008).  While several studies in 
vertebrates have attributed melatonin’s cardio protective properties to its antioxidant 
activity (Reviews: Reiter & Tan, 2003; Tengattini et al., 2007), serotonin has not been 
utilized in such experiments because, unlike melatonin, it also increases heart rate.  It is 
also important to note that studies showing anti-arrhythmic effects of melatonin in  
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hamsters and rats were in conjunction with oxidative stress caused by ischemia-
reperfusion damage.  Melatonin was able to reduce oxidative stress caused by ischemia-
reperfusion injury, and thereby reduce the incidence of post-ischemic-reperfusion 
induced ventricular tachycardia (VT) and ventricular fibrillation (VF) (Bertuglia & 
Reiter, 2007). 
The experiments carried out in this study report on the immediate anti-
arrhythmic effects of melatonin when injected directly over the dorsal vessel and 
pacemaker of Drosophila pupae with no oxidative stress incurred by the animal.  Also, if 
melatonin’s anti-arrhythmic effects are owing to its antioxidant properties, one would 
expect serotonin to have similar anti-arrhythmic effects, which is not the case. 
 In support of melatonin’s anti-arrhythmic effects being receptor mediated and 
not antioxidant mediated, I designed experiments to inject concentrations of ascorbic 
acid (vitamin C) into Drosophila pupae.  Results of ascorbic acid injections showed a 
5% and 24% decrease in heart rhythmicity in wild type and slo pupae, respectively  
(See Chapter 2 Results). 
 Based on the above results and discussion and results of ascorbic acid 
experiments in chapter 2 of this manuscript, I believe that it is highly unlikely that 
melatonin’s anti-arrhythmic effects in Drosophila melanogaster are antioxidant 
mediated.  Instead, I hypothesize that melatonin produces these effects by binding to a 
melatonin receptor and initiating a signaling pathway of events that ultimately lead to 
increased heart rhythmicity. 
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 While this hypothesis is well supported by the experiments performed in this 
study and experiments carried out in Chapter 2 of this manuscript, outside speculation 
regarding melatonin’s ability to modulate heart rhythmicity through receptor binding is 
limited and somewhat ambiguous.  Since heart rate and rhythmicity in vertebrates and 
Drosophila are both primarily regulated by pacemaker activity, it makes sense to turn 
our attention to possible direct effects of melatonin on pacemaking.  The pacemaker in 
both organisms comprises an ensemble of ion channels.  The underlying biophysics of 
the oscillatory behavior may vary in detail, but the overall similarities are striking and 
insect research has already carried over into understanding vertebrate mechanisms with 
implications for human health (Bodmer et al., 2005).   
Pacemaking in these organisms is dependent on Ca+2 and K+ ion currents but not 
dependent on Na+ (Irisawa et al., 1993; McCann & Sanger, 1969; McCann, 1963, 1969; 
Miller, 1985).  Many of the heart mutants that I chose to test in these experiments have 
altered heart rate and/or heart rhythms due to mutations in genes that encode both Ca+2 
and K+ ion channels and calcium signaling pathways involved in pacemaker function of 
the heart.  Human homologues of these genes have also been identified (see 
Introduction).  As mentioned above, heart rhythmicity is increased with injection of 
melatonin in wild type and all heart mutants tested.  There does appear to be a positive 
correlation between percentage increase in heart rhythmicity and the potassium channel 
mutations ether-a-go-go and slowpoke with heart rhythmicity increase ranging from 91-
104%, which would indicate that melatonin may be directly affecting K+ ion channels in 
a way that mitigates the effect of the mutated channel. 
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I also tested a mutation that affects the level of sodium channel activity and, at 
high temperature, causes paralysis associated with a loss of action potentials.   napts is a 
gain-of-function allele of  maleless (mle), a gene required for X chromosome dosage 
compensation and male viability (Kernan et. al, 1991).  napts slows heartbeat and renders 
it less rhythmic and prevents the heart from responding to temperature with an altered 
rate (Dowse et al., 1995).   It has also been shown that even at permissive temperature, 
napts suppresses the effects of a variety of mutations (Shaker, ether-a-go-go, 
Hyperkinetic) that affect potassium channels and cause increased membrane excitability 
(Ganetzky & Wu, 1982).  Melatonin did increase heart rhythmicity in napts mutants by 
84%.  Even though pacemaking in both vertebrates and invertebrates has been shown to 
be independent of Na+ ion currents, it is possible that this gain-of-function allele may be 
exerting its effects on the heart by interacting with potassium and/or calcium ion 
channels in the Drosophila pacemaker. 
The other two mutations that I tested were not specific mutations of calcium 
channels, but rather were ones that affect calcium transport into the sarcoplasmic 
reticulum (Ca-P60AKum170) and the calcium-calmodulin signaling pathway via 
interactions with a cAMP-specific phosophodiesterase encoded by dnc1.   
Ca-P60AKum170 is an EMS-induced mutant that affects sarco-endoplasmic 
reticulum calcium ATPase (SERCA), a membrane protein that pumps free cytosolic 
calcium into intracellular stores.  Abnormalities in the amount or structure of the 
SERCA protein have been linked to cardiac malfunction in mammals.  One of the most 
consistently observed abnormalities in patients with ventricular arrhythmias is the 
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impaired ability to handle intracellular calcium due to changes in ryanodine receptor 
(RyR) and sarco-endoplasmic reticulum Ca2+ - ATPase (SERCA) (Wolk, 2000). 
  This Drosophila SERCA mutant shows a severe decrease in heart rhythmicity 
after being subjected to a 2.5 minute heat shock at 41̊ C (Sanyal et al., 2006).  When 
these pupae were injected with melatonin before heat shock, they showed an increase in 
heart rhythmicity of 137%.  When these pupae were injected with melatonin after heat 
shock, they showed an increase in heart rhythmicity of 123%.  I attribute the difference 
in the results between the two protocols to the fact that melatonin had a longer time to 
exert its effects when injected before heat shocking as wild type flies subjected to the 
same protocols showed a similar trend (170% increase before and 158% after).  Based 
on these results and previous experiments indicating the importance of SERCA and RyR 
in regulating intracellular calcium levels of myocardial cells and maintenance of heart 
rhythmicity, melatonin may have an effect on intracellular calcium levels through 
another pathway or may be affecting ryanodine receptors indirectly.  Experiments with 
Drosophila ryanodine receptor mutants were not performed in this study, but would be 
of interest in the investigation of melatonin’s effects in future experiments. 
Results in this study showed only a 74% increase in heart rhythmicity in dnc1 
mutants. The mutation dunce (dnc1), encodes a cAMP-specific phosphodiesterase 
(PDE), which interacts with the calcium-calmodulin signaling pathway (Walter & Kiger, 
1984).  Turjanski et al., 2004, found that melatonin can modulate this signaling pathway 
by changing the concentration of intracellular calcium via activation of its G protein-
coupled receptors.  It is possible that melatonin is exerting its anti-arrhythmic effects 
through this signaling pathway, but no conclusion can be drawn from this result. 
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Recent research has reported that long term administration of melatonin to 
ventricular fibrillation (VF)-prone spontaneously hypertensive (SHR) and normotensive 
Wistar rats confers protection from lethal arrhythmia because of the increase in the VF 
threshold.  The antiarrhythmic effect of melatonin was associated with the enhancement 
of myocardial  Connexin 43 (Cx43) gene expression as well as the total levels of Cx43 
protein and its functional phosphorylated forms in both SHR and Wistar rat hearts 
(Benova et al., 2013, 2015).  In addition to these findings, Ai et al. 2000, found that  
Wnt-1 is a specific and potent inducer of Cx43 expression in cardiomyocytes and that 
this effect results in enhanced accumulation of Cx43 protein and formation of functional 
gap junction channels. Interestingly, the gene product of wingless (wg), the Drosophila 
Wnt homologue, has been shown to be crucial for normal heart development, where it 
appears to be absolutely required for specifying the heart progenitors (Park et al., 1996, 
1998).  It is also known that mononucleate cardiomyocytes that comprise the heart tube 
in invertebrates such as Drosophila are electrically connected by gap junctions formed 
by innexin (Connexin is the vertebrae homologue).  Perhaps melatonin is having a 
similar effect on the innexins in the Drosophila heart. 
 Although it is highly likely that melatonin is producing its anti-arrhythmic 
effects by binding to a melatonin receptor, the possible mechanisms that affect 
rhythmicity are diverse and complex.  Future research should first focus on positive 
identification and characterization of a melatonin receptor in Drosophila (See Chapter 
2).  Melatonin’s anti-arrhythmic pathway would be open to further study were such a 
receptor to be identified and characterized. 
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CHAPTER 2 
ANALYSIS OF MELATONIN ACTION AND POSSIBLE IDENTIFICATION OF 
A MELATONIN RECEPTOR IN Drosophila melanogaster 
Abstract 
Melatonin injection into P1 pupae of Drosophila melanogaster results in an 
acute and profoundly significant increase in heart rhythmicity ranging from 47-151% 
without altering heart rate of the organism.  In the present study luzindole, a non-
competitive melatonin antagonist; 2-iodomelatonin, a high affinity melatonin agonist; 
and ascorbic acid, a powerful antioxidant are injected into Drosophila wild-type and 
heart mutant pupae in order to investigate melatonin’s anti-arrhythmic mechanisms.  
Animals injected with luzindole and melatonin showed no significant increase in heart 
rhythmicity in wild type or heart mutant pupae showing that luzindole was able to block 
melatonin’s anti-arrhythmic effects.  Animals injected with 2-iodomelatonin showed an 
11 % and 15 % greater increase in heart rhythmicity than melatonin in wild type and 
slowpoke (slo).  Wild type and slo pupae injected with ascorbic acid showed a 
significant decrease in heart rhythmicity.  Results from all three injected substances 
provide strong support for the hypothesis that melatonin’s anti-arrhythmic effects are 
receptor mediated as opposed to antioxidant mediated.  On the basis of these findings, an 
attempt to identify a possible melatonin receptor in Drosophila melanogaster was made 
by using RNA interference (RNAi) and loss of function tests with four different 
Drosophila orphan G protein-coupled receptors (CG4313, CG3171, CG13579, 
CG13575).  While CG3171, CG13579, and CG13575 showed no loss of function (i.e. 
heart rhythmicity still increased with melatonin injection by 27 %, 26 % and 33 % 
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respectively), CG4313 exhibited loss of function (no significant increase in heart 
rhythmicity with melatonin injection).  This finding indicates that the CG4313 orphan 
receptor may be a melatonin receptor in Drosophila melanogaster. 
Introduction 
Melatonin (N-acetyl-5-methoxytryptamine), an indolamine which is biologically 
synthesized from the amino acid L-Tryptophan, is the methoxy derivative of serotonin.    
The discovered molecule was named melatonin because of its effects on melanin  
(‘mela-’) aggregation in the melanocytes of amphibians (Lerner et al., 1958) and its 
derivation from serotonin (‘-tonin’).  Melatonin is present in the earliest life forms and is 
found in all organisms including bacteria, algae, fungi, plants, insects, and vertebrates 
including humans (Tan et al., 2003).   Although melatonin is typically referred to as a 
hormone, the diversity of actions that it effects do not always comply with the 
conventional definition of a hormone.  A hormone is defined as a molecule that is 
synthesized in an organ, released into a bodily fluid (usually the bloodstream) from 
where it travels to another cell or group of cells were it acts via specific receptors to 
mediate its effects.  Many of melatonin’s affects are not receptor mediated.  It is well 
known that melatonin is a potent antioxidant, even more powerful than vitamin E (Pieri 
et al., 1994).  The ability of melatonin and its metabolites to expunge free radicals and 
related reactants possibly involves all of the following actions: a) direct detoxification of 
radicals and radical products, b) stimulation of the activities of several antioxidative 
enzymes, c) inhibition of the activities of pro-oxidative enzymes, d) promotion of the 
synthesis of glutathione, another essential antioxidant, e) synergistic actions with other 
antioxidants, and f) mitochondrial actions of melatonin that reduce free radical 
63 
 
generation (Reiter et al., 2007).  Melatonin also acts as an autocoid when it is released 
by a cell and acts on another cell in the immediate vicinity (Tan et al., 2003).  In 
mammals, melatonin can also signal intracellular processes via activation of two high-
affinity G-protein-coupled receptors designated MT1 and MT2 (Dubocovich et al., 
1983; Dubocovich & Markowska, 2005; Reppert et al., 1996).  See Introduction for 
more detail on melatonin receptors.  
 Often in preliminary experiments with melatonin, it is unknown whether its 
observed effects are antioxidant or receptor mediated.  This is especially true if 
melatonin receptors have not yet been identified and characterized in the organism that 
is being tested, as is the case with Drosophila melanogaster.  Serotonin (5-
hydroxytryptamine; 5-HT) is a precursor to melatonin.  Four receptors for 5-HT have 
been described in Drosophila: one shares sequence homology to the vertebrate 5HT 
receptor type 2 (5HT2R; CG1056), one is similar to the vertebrate serotonin receptor 
type 7 (5HT7R; CG12073) and two show high homology to vertebrate 5HT1 type 
receptor (5HT1AR and 5HT1BR; CG16720 and CG15113, respectively) (Silva et al., 
2014).  Drosophila melanogaster synthesizes its own serotonin (Livingstone, 1981) and 
also has several clusters of serotonergic neurons located in its central nervous system 
(Valles, 1988). 
 Conversion of serotonin to N-acetylserotonin, the direct precursor of the 
melatonin, is catalyzed by serotonin N-acetyltransferase (AANAT) in a reaction 
requiring acetyl coenzyme A (AcCoA) (Hickman et al., 1999).  Two different AANATs 
(AANAT1 and AANAT2) have been identified and characterized in Drosophila 
melanogaster (Hintermann & Meyer, 1995; Brodbeck et al., 1998; Amherd et al., 2000), 
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but it is unknown whether Drosophila makes endogenous melatonin.  Because 
Drosophila and vertebrate serotonin receptors and vertebrate melatonin receptors all 
belong to the G protein-coupled 7-transmembrane family, it is likely that if they exist, 
melatonin receptors in Drosophila would also be of this type.  Analysis of the completed 
Drosophila genomic sequences (Brody & Cravchik, 2000; Adams et al., 2000) identified 
>100 genes encoding G protein-coupled receptors (GPCRs). Further analysis indicated 
that 44 such receptors are likely to have peptide ligands and that the majority of these 
are derived from ancestors for mammalian peptide GPCR genes (Hewes & Taghert, 
2001).  At present, 35 peptide amine GPCRs are functionally characterized in 
Drosophila.  Another 14 GPCRs are predicted to be involved in neuropeptide signaling 
pathways, but their ligands are still unknown and therefore they are classified as 
“orphan” amine receptors (Caers et al., 2012). 
 The use of melatonin agonists and antagonists is a good first approach to 
elucidating melatonin’s effects.  Luzindole is a melatonin receptor antagonist for the 
human MT1 and MT2 receptors (pKi 6.2-6.8 and pKi 7.6-8.1 respectively) (Dubocovich, 
1988).  Luzindole has been used in a number of experiments and acts by blocking 
melatonin’s effects, which supports melatonin’s receptor mediated actions (Blask et al., 
2002; Dubocovich et al., 1998; Leja-Szpak et al., 2010; Rezzani et al., 2006; Roth et al., 
1999; Yu et al., 2014).  2-[125I]iodomelatonin  is a selective, high-affinity ligand for the 
identification and characterization of melatonin receptor sites. The binding affinity of 2-
[125I]iodomelatonin to human MT1 and MT2 receptors displays values of pKi 10.2-11.0 
and pKi 9.7-10.3 respectively (Audinot et al., 2003).  The specific binding of 2-
[1251]iodomelatonin fulfills all the criteria for binding to a receptor site, being stable, 
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reversible, saturable, and of high affinity (Dubocovich & Takahashi, 1987).  2-
[125I]iodomelatonin  binding acts by mimicking the effects of melatonin and has been 
used to identify melatonin receptors in a variety of peripheral tissues in vertebrates 
(Pang et al., 1993). 
  Another deorphanization tool is a loss-of-function approach called RNA 
interference (RNAi).  This  allows us to eliminate targeted gene sequences in an attempt 
to understand their function (Bellés, 2010).  (See Section I Introduction for more details 
on RNA interference.)  Drosophila RNAi is cell-autonomous, and because of this, 
targeted expression of RNAi constructs using the Gal4/UAS system (Brand & Perrimon, 
1993) can be used for cell- or tissue-specific interrogation of gene function. Indeed, this 
approach has been used extensively. 
Typically, different Gal4-driver lines are crossed with UAS-target gene lines, 
and the effects of tissue-specific gene expression are examined in the progeny. The 
Gal4-UAS system provides a number of distinct advantages including promoter 
expression patterns when using UAS-β-galactosidase (UAS-lacZ) or UAS-green 
fluorescent protein (GFP) as a tissue marker; ectopic expression in a variety of tissues, 
and the tissue-specific effects of specific gene knockdown using UAS-RNAi lines 
(Dietzl et al., 2007; Haley et al., 2009).  For example, tinC-GAL4 or GMH5-Gal4 can be 
used to drive cardiac-specific transgenes to express recombinant cDNA to examine 
ectopic protein expression or RNAi to examine specific gene knockdown in the heart 
(Neely et al., 2010; Taghli-Lamallem et al., 2008).  Although these drivers do capture 
the heart it is important to note that they may also include other sites of expression in the 
animal. 
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 The goals of the experiments carried out in this study are twofold: 1. To clarify 
whether melatonin’s anti-arrhythmic effect (shown in Chapter 1) are antioxidant or 
receptor mediated 2. To identify a specific melatonin receptor in Drosophila 
melanogaster. 
The first group of experiments examining melatonin’s antioxidant vs. receptor 
mediated effects involved a series of co-injections of luzindole antagonist and melatonin 
into Drosophila early pupae (P1), and a second series of injections of high affinity 
agonist 2-[125I]iodomelatonin or ascorbic acid (vitamin C).  The second group of 
experiments attempted to implicate a Drosophila orphan receptor using paired specific 
receptor RNAi strains crossed with the GMH5-Gal4 heart specific driver and then 
injecting melatonin.  A knock-down of the orphan receptor combined with loss-of-
function with melatonin injection (no increased heart rhythmicity) would implicate a 
melatonin receptor 
Materials and Methods 
Fly Cultures and Strains 
All mutant and control strains were maintained in 250ml bottles in a 12:12 light: 
dark (L:D) cycle under uncrowded conditions in a humidified, temperature-controlled 
incubator at 25º Con malt-molasses-cornmeal-agar medium.  No population bottlenecks 
occurred.  Propionic acid was added to the medium to control mold growth (Jennings et 
al., 2009).   
 
 
67 
 
Genetics 
Homozygous individuals of the following Drosophila melanogaster strains were tested: 
Canton-S (CS) wild-type 
no action potential temperature sensitive (napts) (Wu et al., 1978) 
slowpoke  (slo) (Elkins et al., 1986) 
 
RNAi strains and crosses 
 The heart-specific driver employed here is GMH5–Gal4, a 900-bp heart 
enhancer fragment 73 from the tinman gene (Bodmer 1993; Venkatesh et al., 2000) that 
was cloned into the P{GaWB} vector upstream of the Gal4 sequences. This driver was 
enhanced with multiple copies of a UAS–Gal4 element allowing stronger myocardial 
expression when activated in late embryonic or during adult stages (Wessells & Bodmer, 
2004). 
RNAi strains of Drosophila melanogaster of G-protein coupled orphan receptors tested: 
CG 4313 RNAi  (FlyBase ID: FBgn0025632) 
CG 3171 RNAi  (FlyBase ID: FBgn0046687) 
CG 13579 RNAi  (FlyBase ID: FBgn0014445) 
CG 13575 RNAi  (FlyBase ID: FBgn0034996) 
Ten virgin females of each RNAi strain were collected and crossed with ten 
GMH5 males.  In addition, a reciprocal cross of ten GMH5 virgin females and  
ten CG4313 RNAi males was carried out based on the results of possible melatonin 
receptor identification from the original CG4313 RNAi cross.  Crosses were maintained 
in 250ml bottles under the same environmental conditions described above. 
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 First generation (F1) pupae from these crosses were injected with 1000 µM 
melatonin and heart rhythmicity and frequency were recorded.  If melatonin injection 
still caused an increase in rhythmicity, the silenced orphan receptor was eliminated.  If 
melatonin injection did not cause an increase in rhythmicity, the orphan receptor was 
considered a candidate melatonin receptor. 
Measurement of Heartbeat 
See Materials & Methods, Chapter 1 
 
Pharmacology of melatonin, luzindole and 2-[125I]iodomelatonin and L-ascorbic 
acid 
Melatonin is insoluble in water and must initially be dissolved in ethyl alcohol.  
For consistency, melatonin, luzindole, 2-[125I]iodomelatonin and L-ascorbic acid were 
first dissolved in 1 % ethyl alcohol and then added to Calcium-free Drosophila Ringer’s 
solution (Ashburner, 1989).  Concentrations of 2500 µM, 1000 µM, 500 µM, 100 µM, 
and 50 µM melatonin were prepared to assay dose response.   
Luzindole is a melatonin receptor antagonist for the human MT1 and MT2 
receptors (pKi 6.2-6.8 and pKi 7.6-8.1 respectively) (Dubocovich, 1988).   
2-[125I]iodomelatonin  is a selective, high-affinity ligand for the identification and 
characterization of melatonin receptor sites. The specific binding of  
2-[125I]iodomelatonin fulfills all the criteria for binding to a receptor site, being stable, 
reversible, saturable, and of high affinity (Dubocovich & Takahashi, 1987).  The binding 
affinity of 2-[125I]iodomelatonin to human MT1 and MT2 receptors displays values of 
pKi 10.2-11.0 and pKi 9.7-10.3 respectively (Audinot et al., 2003).  Single 
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concentrations of 2500 µM luzindole, and 1000 µM 2-[125I]iodomelatonin were 
prepared.   Based on the melatonin dose assay results, the standard concentration used 
for ensuing experiments of melatonin and 2-iodomelatonin injections was 1000 µM.  A 
higher dose of (2500 µM) was used for luzindole to ensure that any melatonin receptors 
present would be completely blocked by the antagonist. 
Melatonin exhibits both receptor mediated and antioxidant mediated effects.  As 
a powerful antioxidant, melatonin has been shown to be more effective than vitamin C 
(ascorbic acid) and vitamin E in combating paraquat induced oxidative stress in 
Drosophila melanogaster (Bonilla et al., 2006).  Injections with ascorbic acid in 
Drosophila wild-type and slowpoke pupae will help to ascertain whether melatonin’s 
effects on heart rhythmicity are receptor or antioxidant mediated.   
Solutions were perfused directly over the pacemaker and caudal region of the 
dorsal vessel by injection into the caudal end of the animal (Johnson et al., 1997).  Glass 
electrodes were used for injection and were pulled on a World Precision Instrument 
PUL-100 micropipette puller.  Tips were gently broken to assure sharpness. 
Following a 10 minute pre-injection recording, the pupa was placed under an 
Olympus dissecting scope for injection.  A World Precision Instrument Nanoliter 
Injector (model # A203XVY) was calibrated to administer 46 nl volume of liquid.  A 
micromanipulator was used to position the glass electrode in the dorsal posterior region 
near the caudal region of the heart.  Heartbeat was recorded for 10 minutes before 
injection and for 10 minutes immediately (within 1 minute) after injection of a substance 
as delineated above. 
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Specifics of tests with luzindole 
In addition to the protocol for melatonin and 2-[125I]iodomelatonin, CS, slo and 
napts were subjected to the following protocol.  After pre injection recording of 
heartbeat, P1 pupae were injected with 46 nL of 2500 µM luzindole, then allowed 1.5 
minutes of rest, and then injected with 46 nL of 1000 µM melatonin before post 
injection heartbeat recording. 
Owing to its clear, well-known and immediate effects of increased heart rate, I 
used epinephrine and a beta-blocker (metoprolol) to establish the double injection 
protocol.  An initial 10 minute pre-injection recording of heart rate and rhythmicity was 
performed. 
Analysis of heartbeat data 
See Materials & Methods, Chapter 1 
Results 
Effects of injections of melatonin alone and double injections with luzindole and 
melatonin in wild type, slowpoke and napts pupae 
Both wild-type and pupae bearing heart mutations injected with 1000 µM 
melatonin showed significant increase in heart rhythmicity ranging from 54 to 91% 
(Table 2.1 and Fig. 2.1) 
When the same strains were injected first with 2500 µM luzindole, allowed to 
rest for 1.5 minutes, and then injected with 1000 µM melatonin, a significant decrease in 
heart rhythmicity was observed in wild-type pupae ( F(1,14) = 18.6; p < 0.001), but no 
significant increase in heart rhythmicity (Table 2.2 and Fig. 2.1). 
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Table 2.1  Effects of melatonin injection on heart rhythmicity in wild-type and heart 
mutants 
 
 
Genotype 
   Meltonin         
Injected 
   µmol-1a 
 
Mean 
RI 
Pre 
25´C 
Mean
RI 
Post 
25´C 
      
% 
Change 
 
  N 
 
  +/-SEM 
Pre/Post 
 
F Value 
 
P Value 
 Canton-S (+) 1000 0.449 
 
0.694 
 
+ 54% 30 0.02/0.02 (1,29) 158.7 <2.2e-16 *** 
napts 1000 0.406 
 
0.746 
 
+ 84% 30 0.02/0.01 (1,29) 338.6 < 2.2e-16 *** 
slo 1000 0.357 
 
0.681 
 
+ 91% 42 0.02/0.01 (1,41) 61.4 9.29e-14 *** 
 
aConcentration of melatonin injected 
bMean Rhythmicity Index pre-injection minutes 4-7 
cMean Rhythmicity Index post-injection minutes 4-7 
*** p < 0.001 comparing before injection to after melatonin injection within each strain 
 
 
Table 2.2  Effects of double injection of luzindole and melatonin in heart rhythmicity in 
wild-type and heart mutants 
 
 
 
Genotype 
Luzindole/   
Meltonin         
Injected 
µmol-1 
 
Mean 
RI 
Pre 
25´C 
Mean
RI 
Post 
25´C 
      
      
     % 
Change 
 
 
   
N 
 
 
 +/-SEM 
Pre/Post 
 
 
F Value 
 
 
P Value 
Canton-S (+) 2500/1000 0.583 
 
0.480 
 
- 18 %  15 0.03/0.03 (1,14) 18.6 3.78e-05 *** 
napts 2500/1000 0.338 
 
0.288 
 
- 8 %  5 0.03/0.05 (1,40 .001 0.970 
slo 2500/1000 0.378 
 
0.346 
 
-15%  10 0.03/0.03 (1,9) 3.7 0.0583  
 
aConcentrations of luzindole/melatonin injected 
bMean Rhythmicity Index pre-injection minutes 4-7 
cMean Rhythmicity Index post-injection minutes 4-7 
*** p < 0.001 comparing before injection to after luzindole/melatonin injection within   
  each strain 
 
 
 
72 
 
Figure 2.1  Effects of melatonin alone and luzindole/melatonin double injections on 
heart rhythmicity in wild-type and heart mutants 
 
Effects of ascorbic acid, 2-iodmelatonin and melatonin on heart rate and 
rhythmicity in wild type and slowpoke pupae 
Injection with 1000 µM 2-iodomelatonin, a high affinity melatonin agonist, 
showed significant increase in heart rhythmicity between 53 % and 141 % in wild type 
and slowpoke pupae respectively (p < 0.001) (Table 2.3 and Fig. 2.2, 2.3). 
Ascorbic acid (vitamin C) is a powerful antioxidant.  When 1000 µM 
concentrations were injected into wild type and slowpoke pupae, no significant change 
in heart rhythmicity was observed (Table 2.4, Fig 2.2, 2.3). 
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Injections of 2-iodomelatonin had no significant effect on heart rate in either 
wild type or slowpoke pupae (Table 2.5, Figs. 2.4, 2.5). 
 Injection of ascorbic acid showed significant decrease in heart rate in both wild 
type and slowpoke pupae (p < 0.001) (Table 2.6, Figs. 2.4, 2.5). 
 
Table 2.3  Effects of 2-Iodomelatonin injection on heart rhythmicity in wild-type and 
slowpoke pupae 
 
 
Genotype 
2-Iodomelatonin             
Injected 
µmol-1a 
 
Mean 
RI 
Pre 
25´C 
Mean
RI 
Post 
25´C 
      
     % 
Change 
 
  
N 
 
 +/-SEM 
Pre/Post 
 
F Value 
 
     P Value 
Canton-S (+) 1000 0.519 
 
0.796 
 
53% 
 
5 0.03/0.01 (1,4) 30.3 6.92e-06 *** 
slowpoke 1000 0.256 
 
0.618 
 
141% 5 0.03/0.01 (1,4) 139.9 2.08e-12 *** 
 
aConcentration of 2-Iodomelatonin injected 
bMean Rhythmicity Index pre-injection minutes 4-7 
cMean Rhythmicity Index post-injection minutes 4-7 
*** p < 0.001 comparing before injection to after 2-iodomelatonin injection within each   
  strain 
 
Table 2.4  Effects of ascorbic acid injection on heart rhythmicity in wild-type and 
slowpoke pupae 
 
 
Genotype 
Ascorbic 
Acid             
Injected 
µmol-1a 
 
Mean 
RI 
Pre 
25´C 
Mean
RI 
Post 
25´C 
      
        
     % 
Change 
 
    
   
N 
  
 
+/-SEM 
Pre/Post 
 
 
  F Value 
 
 
    P Value 
Canton-S (+) 1000 0.551 
 
0.513 
 
    -7 % 
 
10 0.03/0.03 (1,9) 0.13 0.718 
slowpoke 1000 0.244 
 
0.198 
 
   -19 % 10 0.03/0.02 (1,9) 1.6 0.217 
 
aConcentration of ascorbic acid injected 
bMean Rhythmicity Index pre-injection minutes 4-7 
cMean Rhythmicity Index post-injection minutes 4-7 
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Figure 2.2  Effects of ascorbic acid, 2-iodomelatonin and melatonin on heart 
rhythmicity in wild-type pupae 
 
Figure 2.3  Effects of ascorbic acid, 2-iodomelatonin and melatonin on heart 
rhythmicity in slowpoke pupae 
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Table 2.5  Effects of 2-iodomelatonin injections on heart rate in wild-type and slowpoke 
pupae 
 
 
Genotype 
2-Iodomelatonin                  
Injected 
µmol-1 
 
Mean
Heart 
Rate 
Pre 
25´C 
Mean
Heart 
Rate 
Post 
25´C 
        
      % 
 Change  
      
 
 
 N 
 
 
  +/-SEM 
Pre/Post 
 
 
F Value 
 
 
P Value 
Canton-S (+) 1000 2.26 
 
2.27 
 
0% 5 0.06/0.04 (1,4) 0.01 0.906 
slowpoke 1000 2.11 
 
2.13 
 
+1% 5 0.04/0.06 (1,4) 1.2 0.322 
 
aConcentration of 2-Iodomelatonin injected 
bMean heart rate pre-injection minutes 4-7 
cMean heart rate minutes 4-7 
 
 
Table 2.6  Effects of ascorbic acid injections on heart rate in wild-type and slowpoke 
pupae 
 
 
    Genotype 
  Ascorbic 
Acid             
Injected 
   µmol-1 
 
Mean 
Heart 
Rate 
Pre 
25´C 
Mean
Heart 
Rate 
Post 
25´C 
        
          
    %   
Change    
 
 
  N   
       
 
 +/-SEM 
Pre/Post 
 
 
   F Value 
 
 
     P Value 
Canton-S (+) 1000 2.39 
 
2.25 
 
 
    -6 %   10 0.04/0.04 (1,9) 22.2 1.38e-05 *** 
slowpoke 1000 2.18 
 
1.86 
 
   -15 % 10 0.04/0.05 (1,9) 17.3 9.71e-05 *** 
 
aConcentration of ascorbic acid injected 
bMean heart rate pre-injection minutes 4-7 
cMean heart rate minutes 4-7 
*** p < 0.001 comparing before injection to after ascorbic acid injection within each 
  strain 
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Figure 2.4  Effects of 2-iodomelatonin, ascorbic acid and melatonin injections on heart 
rate in wild-type pupae 
 
Figure 2.5  Effects of 2-iodomelatonin, ascorbic acid, and melatonin injections on heart 
rate in slowpoke pupae 
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Effects of melatonin injection on four different orphan receptor RNAi strains 
crossed with GMH5-Gal4 heart driver 
Repeated measures ANOVAs showed significant effects of melatonin injection 
in CG3171, CG13579 and CG13575 orphan receptor strains (p < 0.05).  This correlates 
strongly with the results of absolute % increase in rhythmicity ranging from 20 to 38 % 
in these three strains.  These results indicate that no loss of function with melatonin 
injection (Table 2.7, Fig. 2.6). 
Upon initial testing, CG4313 showed promising results based on the strong but 
not significant trend and 20 animals were tested (10 each of reciprocal crosses).  Results 
of melatonin injection with this orphan receptor RNAi continued to show no increase in 
heart rhythmicity (p > 0.05) (Table 2.7, Fig. 2.6).  This loss of function result implicates 
that his CG4313 is a highly likely candidate for a melatonin receptor in Drosophila 
melanogaster. 
 
 
 
 
 
 
 
78 
 
Table 2.7  Effects of melatonin injection on heart rhythmicity in orphan receptor RNAi  
crossed with  GMH5-Gal4 driver 
Orphan 
Receptor 
RNAi 
Meltonin     
Injected 
µmol-1a 
 
Mean 
RI 
Prec 
25´C 
Mean
RI 
Postd 
25´C 
 
% 
Change 
 
N 
 
+/-SEM 
Pre/Post 
 
F Value 
 
P Value 
CG4313a 1000 0.580 
 
0.588 
 
+ 2% 10 0.04/0.03 (1,9) 0.12 0.730 
CG4313b 1000 0.507 
 
0.494 
 
 - 2% 10 0.04/0.04 (1,9) 0.13 0.720 
CG3171 1000 0.680 
 
0.817 
 
+20 % 5 0.03/0.04 (1,4) 12.2 0.00161 ** 
CG13579 1000 0.649 
 
0.817 
 
+26 % 5 0.05/0.03 (1,4) 33.7 3.08e-06 *** 
CG13575 1000 0.491 
 
0.679 
 
+38% 5 0.07/0.04 (1,4) 14.2 0.000791 *** 
 
a orphan receptor RNAi virgin females crossed with GMH5 Gal 4 males 
b GMH5  Gal4 virgin females crossed with orphan receptor RNAi males 
c Mean Rhythmicity Index pre-injection minutes 4-7 
d Mean Rhythmicity Index post-injection minutes 4-7 
** p < 0.01 comparing before injection to after melatonin injection within each strain 
*** p < 0.001 comparing before injection to after melatonin injection within each strain 
Figure 2.6  Effects of melatonin injection on heart rhythmicity in orphan receptor 
RNAis crossed with GMHG-Gal 4 driver 
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Discussion 
In this set of experiments, I showed that melatonin’s ability to increase heart 
rhythmicity in Drosophila melanogaster is a result of melatonin receptor binding.  In the 
process of elucidating melatonin’s effects, I also discovered an orphan G protein-
coupled receptor that is highly likely to be a melatonin receptor.  Evidence for these 
findings stem from the results of three different experimental approaches.  I showed:  
1. A highly specific response to melatonin, 2. Effective blocking of melatonin’s effects 
with its antagonist luzindole, 3. Mimicking of melatonin’s effects with its high-affinity 
agonist 2-iodomelatonin, and 4. Loss of function using RNAi techniques to silence a 
specific orphan GPCR. 
The effects of the hormone melatonin on heart rhythmicity in Drosophila 
melanogaster are profound.  Though it is well known that Drosophila has receptors for 
and produces its own serotonin, which is melatonin’s precursor, evidence for the 
presence of melatonin receptors or endogenous production of melatonin in the fruit fly 
has not been presented to date.   Elucidation of whether melatonin’s effects on 
Drosophila’s cardiovascular system are antioxidant mediated or receptor mediated is 
crucial to unraveling the mystery of the mechanisms of this hormone.   
In a previous set of experiments (Chapter 1) I demonstrated that melatonin was 
able to increase heart rhythmicity by 54-104% without affecting heart rate in both wild 
type and heart mutant strains of Drosophila melanogaster.  This was an interesting 
result, especially when compared to serotonin’s opposing effects of increasing heart rate 
without significantly affecting heart rhythmicity (Johnson et al., 1997; VanKirk, 
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unpublished manuscript).  Since a melatonin receptor had not yet been identified in 
Drosophila, it was not clear how melatonin was producing these effects.  A handful of 
studies have been carried out in vertebrates reporting the anti-arrhythmic properties of 
melatonin (Benova et al., 2013, 2015; Bertuglia & Reiter, 2007; Diez et al., 2009; Vazan 
et al., 2005), but most researchers attributed this effect to melatonin’s ability to scavenge 
reactive oxygen species (ROSs) produced during myocardial injury. 
It seemed a logical next step to introduce a melatonin antagonist in my 
experimental design in order to gain a better understanding of melatonin’s activity.  In 
this set of experiments I performed double injections of the non-competitive melatonin 
antagonist, luzindole and melatonin.  Not only did luzindole completely abolish 
melatonin’s anti-arrhythmic effects in wild type, slo and napts pupae, it also showed a 
slight , but non-significant decrease in heart rhythmicity when injected alone in wild-
type and napts pupae and a significant decrease in heart rhythmicity in slo pupae.  This 
would make sense if Drosophila makes melatonin endogenously as luzindole would be 
blocking its effects as well.  This antagonist effect of luzindole can only be exerted 
through receptor-mediated activity, which strongly implicates the presence of melatonin 
receptors in Drosophila melanogaster. 
In a similar group of experiments designed to support the earlier findings, I chose 
to inject wild type and slo pupae with the high-affinity melatonin agonist, 2-
Iodomelatonin.  Results of these experiments showed that 2-Iodomelatonin increased 
heart rhythmicity in slo pupae by 50% more than melatonin, respectively.  These results 
are consistent with the fact that 2-Iodomelatonin shows higher binding affinity to 
melatonin receptors (MT1 and MT2) than melatonin itself (Audinot et al., 2003).  As 
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was the case with luzindole, 2-Iodomelatonin is only able to exert its effects by binding 
to a melatonin receptor, which these results strongly support.  This is another clear 
indication that a melatonin receptor exists in Drosophila melanogaster. 
Melatonin’s cardio-protective effects are known to be antioxidant-related  
(Reviews: Reiter & Tan, 2003; Tengattini et al., 2007).   At present there are several 
lines of evidence which suggest that an increased intake of antioxidants, vitamins, 
ascorbic acid (C), tocopherols (E), and beta-carotene (A), have some protective role in 
the coronary heart disease and other cardiovascular problems (Zhang et al., 2014).  In 
support of melatonin’s anti-arrhythmic effects being receptor-mediated and not 
antioxidant- mediated, I designed experiments to inject concentrations of ascorbic acid 
(vitamin C) into Drosophila pupae.  Results of ascorbic acid injections showed a 5% and 
24% decrease in heart rhythmicity in wild type and slo pupae, respectively.  Even 
though Eslami et al., 2007, report that ascorbic acid, when used as an adjunct to ß-
blockers, is highly effective at reducing post-operative atrial fibrillation, its antioxidant 
properties do not seem to have the same effect on the Drosophila heart.  Instead, these 
results disprove the hypothesis that melatonin’s anti-arrhythmic effects are antioxidant 
related.  Furthermore, studies in vertebrates implicating that melatonin’s anti-arrhythmic 
effects are antioxidant-mediated did not include the use of luzindole in their 
experimental design (Benova et al., 2013, 2015; Bertuglia & Reiter, 2007; Diez et al., 
2009; Vazan et al., 2005). 
Mammalian melatonin receptors are members of the G protein-coupled receptor 
family.  GPCRs represent the largest superfamily and most diverse group of mammalian 
transmembrane proteins. The main characteristic feature of these proteins is that they 
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share a common seven-transmembrane (7TM) configuration (Tang et al., 2012).  A 
broad range of ligands can bind to GPCRs, which result in a variety of signal 
transduction pathways that influence numerous physiological pathways in the body.  
GPCRs are the most prominent family of pharmacological targets in biomedicine 
(Lappano & Maggiolini, 2011). 
The rhodopsin-like (Class A) receptors are the largest and most extensively 
studied subfamily of GPCRs.  Both serotonin (5-HT) receptors and melatonin receptors 
in vertebrates and serotonin receptors in Drosophila fall into this category, so it is 
reasonable to assume that possible melatonin receptors in the fruit fly would also be of 
this type.  The Drosophila melanogaster genes CG4313, CG3171, CG13575 and 
CG13579 code for putative neuropeptide receptors belonging to class A are still orphans 
(Hauser et al., 2006).  Bloomington stock center has RNAi strains for the 
aforementioned genes that can knock down the gene of interest in specific tissues and be 
used for loss of function tests. 
In my final set of experiments I crossed the RNAi strains of four different 
Drosophila orphan GPCRs (CG4313, CG3171, CG13575, CG13579) with the heart 
specific Gal 4 driver, GMH5 in order to silence the orphan receptor in question and 
carry out loss of function tests.  Injection of melatonin into CG3171, C13575 and 
CG13579 crosses all showed significant increase in rhythmicity.   Because RNA 
interference knocks down the gene coding the orphan receptor, an increase in 
rhythmicity with melatonin injection indicates that the melatonin receptor is still present 
and is not coded for by the targeted gene.  However, injections of melatonin into the 
CG4313 silenced pupae showed no significant increase in heart rhythmicity, which 
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indicates that the CG4313 orphan receptor could be a melatonin receptor.  Interestingly, 
of the four orphan receptors tested, the CG4313 orphan receptor also shows the highest 
homology (~ 30%) to the human melatonin receptor. 
In summary, the combination of pharmacology and genetics described above 
provide data that support the receptor mediated anti-arrhythmic effects of melatonin and 
the presence of a melatonin receptor in Drosophila melanogaster.  Coupling a ligand 
such as melatonin to an orphan receptor will provide invaluable information as to the 
signaling pathway that underlies melatonin’s anti-arrhythmic effects. 
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APPENDIX 
THE RELATIONSHIP OF HEART FUNCTION TO TEMPERATURE IN 
Drosophila melanogaster AND ITS HERITABILITY 
Abstract 
  We measured heart rate and rhythmicity (regularity) of heartbeat in Drosophila 
melanogaster at five different temperatures (20, 25, 30, 35, and 37 C.), for a Florida 
population and estimated the narrow-sense heritability of both traits.  Heritability of 
heart rate ranged from 0.16 to 0.24, but was statistically significant only at 20 (h2 = 
0.24) and at 30 (h2 = 0.23).  The heritability of heartbeat rhythmicity ranged from –
0.034 to 0.11, and was not significant at any temperature.  Heart rate increased linearly 
with increasing temperature; the temperature-dependence of heart rate was itself 
heritable (h2 = 0.29).  Heart rhythmicity varied curvilineanearly and was well-
represented by a parabolic function, peaking at about 27 suggesting a temperature 
optimum.  The regularity of the heartbeat did not covary with heart rate except at 20.  
Neither heart rate nor regularity covaried with the change in heart rate with temperature.  
For this population of D. melanogaster, we conclude that there is substantial genetic 
variation for the mechanism whereby the cardiac pacemaker reacts to changes in 
temperature, but not for the cardiac pacemaker's rhythmicity.  The small values of h2 for 
temperature-specific heart rate and heartbeat rhythmicity suggest that these traits are 
adaptive. 
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Introduction 
 
The Drosophila heart, or dorsal vessel, is located medially and dorsally in the 
hemocoel and transports hemolymph through the larval and adult body cavity (Miller, 
1950; Rizki, 1978; Curtis et al., 1999).  The anterior third of the dorsal vessel forms the 
aorta.  The posterior segment, or heart proper, contains three pairs of openings called 
ostia to admit hemolymph  
( Rizki, 1978; Curtis et al., 1999; Wasserthal, 2007).  Heart pacemaking in Drosophila is 
myogenic (Dowse et al., 1995; Gu & Singh, 1995; Bodmer et al., 2005) , and originates 
from a caudal pacemaker (Rizki, 1978), an assembly of ion channels, including those 
passing Ca2+ and K+, interacting in an oscillatory manner (Dowse et al., 1995; Johnson 
et al., 1998; Bodmer et al., 2005).  The beat consists of a contraction phase (systole) and 
a relaxation phase (diastole) ( Rizki, 1978; Curtis et al., 1999; Wasserthal, 2007).  
Heartbeat may reverse requiring nervous control of a second anterior pacemaker (Dulcis 
& Levine, 2003; Wasserthal, 2007).   
Increasing temperature raises heart rate in the fly (Rizki, 1978; White et al., 
1992; Dowse et al., 1995; Ashton et al., 2001;  Ray & Dowse, 2005).  The precise 
mechanism of this change is not understood.  It is of considerable interest to know how 
the heart reacts to temperature changes and what factors influence any such reactions.  
That there may be a strong genetic component is suggested by tests of flies bearing the 
mutations no action potentialTS (napTS) and slowpoke (slo), phenotypes of which include 
attenuation or elimination of the response of the heart to temperature (Dowse et al., 
1995; Johnson et al., 1998).  Using a deficiency screen QTL approach,  
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Ashton et al., (2001) identified nine areas of the genome that either increased or 
decreased P1 heart rate. 
There appears to be one report of narrow-sense heritability of heart rate for D. 
melanogaster (Robbins et al., 1999).  They measured heart rate in inbred lines from 
many geographic locations, and therefore this work gives an estimate that includes 
variation between as well as within a population.  Temperature in this work was likely 
ambient.  Because both the rate and the regularity of the heartbeat in Drosophila are 
temperature-sensitive, we monitored heart function in a single population at five 
temperatures across the wide range of 20 to 37, and determined narrow-sense 
heritabilities of these traits within and across temperatures. 
Materials and Methods 
Fly culture and the experimental population 
A laboratory population was established by mass-mating the progeny of 35 wild, 
inseminated D. melanogaster females collected in Tampa, Florida.  Thereafter, the 
population was maintained in twelve 250-ml culture bottles containing malt-molasses-
yeast-cornmeal-agar medium (0.5% propionic acid added to the medium to control mold 
growth).  A Tomac® tissue was added to each culture bottle to promote pupation out of 
the culture medium.  Flies were cultured at 25 C in a 12:12 Light:Dark cycle in a 
humidified incubator.  Approximately 200 adults were transferred to fresh medium in 
each bottle when subculturing.   
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As necessary, adults were sexed under CO2 anesthesia.  Adults were transferred 
either by tapping groups from one culture vessel to another or by gentle aspiration of 
individuals. 
 Individual crosses were carried out in 35-ml vials, using the same culture 
conditions as described above, but without a tissue added to the medium. 
Measurement of heartbeat 
All test subjects were collected at the third-instar larval stage just as they were 
entering the early pupal (P1) stage.  At this point, they are translucent, making any heart 
movements transmitted to the surrounding organs easily visible.   Each pupa was placed 
on a glass slide in a drop of distilled water and set in the light beam of an Olympus 
binocular microscope.  The light source was powered by a DC supply to eliminate 60 Hz 
variation.  The water served to increase the brilliance of the illumination passing through 
the pupa, and also helped in heat transfer from the slide as the temperature was varied.  
The pupa was adjusted so that one clear portion of the abdomen filled the field of view 
with just the surrounding fat bodies visible.  The movement of these organs results in a 
variation in illumination that can be detected by a phototransistor.  This signal is 
amplified and recorded in a microcomputer through a DAS8 AD converter.  
Temperature of the slide was maintained with a Sensortek TS-4 unit, however it was not 
possible to record temperatures within the animals.   Recording was done at five 
different temperatures (20, 25,  30, 35, 37).  For each pupa, 30 seconds of recording 
was performed at each temperature.  In between measurements 1.5 minutes of 
acclimation time was allowed.   
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Analysis of heartbeat 
Data from individual flies taken at each temperature were analyzed by 
autocorrelation (Chatfield, 1980) and Maximum Entropy Spectral Analysis (MESA)  
( Ulrych & Bishop, 1975; Dowse & Ringo, 1989; Levine et al., 2002; Dowse, 2009).  
Estimates of heart rate were based on the spectral analysis, autocorrelation, and 
inspection of the raw data plots. 
Rhythmicity of heartbeat results in recurring positive and negative peaks in the 
autocorrelogram, and the decay envelope reflects regularity in the signal (Chatfield, 
1980).  The value of the correlation coefficient at the second peak is the rhythmicity 
index.  The value at lag zero is always one (Dowse et al., 1995; Levine et al., 2002; 
Dowse, 2009).  Empirically, we observe that as rhythmicity index decreases, there are 
more skipped beats, irregular intervals between beats, periods of heartbeat cessation, and 
rate variations with time (Johnson et al., 2000; Levine et al., 2002; Dowse, 2009). 
The temperature-dependences of heart rate and rhythmicity index were estimated 
for each individual from least-squares regression (temperature on heart rate or 
rhythmicity index); the resulting slopes were our measures of each phenotype.  We also 
did this regression for all individuals pooled together across families to get values for the 
entire population.  
We tested whether there was a relationship between frequency of heartbeat and 
the rhythmicity index at each of the test temperatures.  We also queried whether either 
frequency or rhythmicity of heartbeat were related to the slope of the regression line of 
temperature on frequency at the temperature at which the hearts were most rhythmic, 
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25.  We computed correlation coefficients (r) individually in EXCEL for each of the 
above interactions across all test animals and asked if r > 0 using a two-tailed t-test 
(Schefler, 1969) (N = 317, df = 315, t = 1.968). 
Crosses and heritability 
The heartbeat of white pupae randomly selected from the general stock 
population was measured without knowing sex.  Each pupa was reared in isolation in a 
35-ml culture vial.  Families were established from these individuals.  When these flies 
eclosed, individual virgin pairs were isolated as parents of families to be tested further.  
Each such family was reared in a 35-ml culture vial.  Heartbeat was monitored in four 
randomly selected offspring of each family when those offspring reached the white pupa 
stage.  Fifty families were so studied.   
 At each temperature, narrow-sense heritability (h2) was calculated for heart rate 
and rhythmicity by least squares regression of the mean parental (mid-parent) values on 
the means of the four offspring within a family.  The slope of this regression line is the 
estimate of h2 (Falconer, 1960).  Further, we estimated the heritability of the response to 
temperature by calculating mid-parent and mean offspring values for each family from 
the slopes derived from the individual regressions of temperature on rate and 
rhythmicity for each individual.  We then regressed mean mid-parent values on mean 
offspring values.   In all tests of significance, α = 0.05.  
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Results 
Effects of temperature on heart rate frequency and rhythmicity 
Across the range tested for all subjects pooled, heart rate increases monotonically 
with temperature and is well-represented by a straight line (slope = 0.09; intercept = 
0.23; r2 = 0.67) (Fig. A.1a).  Given the strength of this linear relationship, we tested the 
fit of the data according to the method of Arrhenius wherein ln(rate) = lnA – Ea/RT, 
where A is the “pre-exponential”, or intercept of the plot, Ea is the activation energy of 
the system in Kcalmol-1, T is the temperature in K, and R is the gas constant (1.985877 
calK-1 mol-1) (Pilling & Seakins, 1996).  Arrhenius plots have been shown to be of use 
in other than studies of simple chemical reaction, having been applied to a wide range of 
processes ranging from cricket chirping to the rate of heartbeat in the terrapin (Laidler, 
1972).  The regression of 1/T on ln(rate) is a good fit (r2 =  0.64).  This yields an 
activation energy of ~6000 Kcalmol-1.  The Q10 for this relationship across the common 
physiological range of 20 to 30 is 1.44.  (Q10 = heart rate at 30/heart rate at 20.) 
We did a similar analysis for all animals across temperature for the rhythmicity 
index.  This statistic has a nonlinear relationship to temperature, highest in the mid-
range between 25º and 30º C, falling off at the extreme temperatures.  We did linear 
regression, and find there is a weakly significant linear relationship (r2 = 0.03), but 
clearly this is not a good description of the data.  We next fit a parabola to the data 
which offers an exceptionally good representation (r2 = 0.88).  The estimated peak 
occurs at ~27º (Fig A.1b).  
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Correlations among heart rate, rhythmicity index and response to changing 
temperature 
There was a significant correlation between heart frequency and rhythmicity 
index only at 20º (r = 0.252, t = 4.62) (See materials and Methods above for details of 
test).  Relationships at all other temperatures were not significant (25º: r = 0.056, t = 
0.99; 30º: r = 0.024, t =  0.4366: 35º, r = -0.029: t = -0.515; 37º: r = -0.077, t = -1.37).   
At 25º, at which temperature the rhythmicity index was near maximum, frequency of 
heartbeat is not correlated with the slope of the regression line (r = 0.135, t = 0.135), nor 
is rhythmicity index (r = -0.08, t = -0.08) (see Materials and Methods above for details 
of test). 
Heritability of heart rate, rhythmicity, and temperature-dependence of heart rate 
Heritability of heart rate calculated at the five test temperatures ranged from 0.16 
to 0.24, and the heritability of the heartbeat rhythmicity index ranged from –0.034 to 
0.11; Table A.2.  Heritability of heart rate was statistically significant (based on 
significance of the regression analysis itself) at 20 (h2 = 0.24) and at 30 (h2 = 0.23); 
Table A.1.  The estimates of heritability of rhythmicity index was not significant at any 
temperature (Table A.2).   
 In the test of heritability of response to change in temperature, in which we 
regressed mean filial slopes for each family on mid parent values, we found a clear 
result.  A significant portion of the variance among slopes was genetic:  h2 = 0.29, r2 = 
0.08, t = 2.398, df = 50, P = 0.02 (Figure A.3) 
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Table A.1.   Heritabilities for heart rate. 
 
Temperature Heritability 
(h2) 
      r2     t value  Degrees of 
freedom (df)        
  P   value 
        20ºC 0.239* 0.18 3.414 50 0.001 
        25ºC 0.170 0.03 1.759 50 0.085 
        30ºC 0.230* 0.08 2.308 50 0.025 
        35ºC 0.165 0.03 1.586 50 0.119 
        37ºC 0.178 0.05 1.875 50 0.067 
*Significant 
 
Table A.2  Heritabilities for rhythmicity indices. 
 
Temperature Heritability 
(h2) 
      r2     t value  Degrees of 
freedom (df)        
  P   value 
        20ºC -0.034 -0.02 -0.311 50 0.757 
        25ºC 0.019 -0.02 0.231 50 0.818 
        30ºC 0.110 -0.01 0.854 50 0.397 
        35ºC 0.057 -0.01 0.599 50 0.551 
        37ºC 0.083 0.00 0.884 50 0.381 
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FIGURE LEGENDS 
 
Figure A.1.  Response of heart rate and rhythmicity to change in temperature.  (a) 
Regression of temperature on frequency for all animals (N=300, r2 = 0.67).     
Parameters of regression equation shown bottom right.  Means indicated by diamond 
symbols,  S.D.  Regression equation: y = 0.09x + 0.024.  b)  Results of nonlinear 
regression, fitting a parabola to the rhythmicity index as a function of temperature for all 
flies (N = 300, r2 = 0.88).  Means indicated by diamond symbols,  S.D.  Regression 
equation: y = -0.0018(x – 26.94)2 + 0.7. 
 
Figure A.2.  Regression analyses of mid parent heart rate on mean offspring heart rate. 
This analysis yields narrow-sense heritability of the trait, h2.   (a) 20ºC  (Equation: y = 
0.24x + 1.48). (b) 30ºC (Equation: y = 0.23x + 2.2).  Regressions done at 25ºC, 35ºC and 
37ºC were not significant (data not shown).   
  
Fig A.3.  Regression of mid-parent on filial mean slopes derived from individual 
regressions of temperature on heart rate for all flies.  The narrow-sense heritability of the 
response to temperature was significant.  Parameters of the regression equation are 
shown bottom right. h2 = 0.29.  Regression equation: y = 0.29x + 0.07. 
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Figure A.1  Response of heart rate and rhythmicity to change in temperature 
 
a) Regression of temperature on frequency for all animals 
 
 
  
b) Results of nonlinear regression, fitting a parabola to the rhythmicity 
index as a function of temperature for all flies 
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Figure A.2  Regression analyses of mid parent heart rate on mean offspring heart 
rate 
 
a) At 20 ̊ C 
 
 
 
 
 
b) At 30 ̊ C 
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Figure A.3  Regression of mid-parent on filial mean slopes derived from individual 
regressions of temperature on heart rate for all flies 
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Discussion 
In D. melanogaster, heart rate increased with increasing temperature, a result 
consistent with previous fly studies (Rizki, 1978; Dowse et al., 1995; Ashton et al., 
2001;  Ray & Dowse, 2005) and studies in other insects (Crozier & Federighi, 1925; 
Fries, 1926).  This is to be expected for poikilotherms, in which the rate of most 
physiological processes vary positively with temperature (Sweeny & Hasting, 1960; 
Winfree, 1980).  In contrast, heart rhythmicity varied with temperature in a non-linear 
way:  it was lower at extreme temperatures than at intermediate temperatures, the latter 
being close to the optimum for the survival and reproduction of this species (Ashburner, 
1989).  It is provocative that two important characteristics of heart function, rate and 
regularity, have very different relationships to changes in temperature as shown in Fig. 
A.2. 
  Narrow-sense heritability of heart rate in the Florida population ranged between 
0.16 and 0.24 and was temperature-dependent.  The two largest heritabilities for this trait 
were for heartbeat measured at 20 (h2 = 0.24) and 30 C (h2 = 0.23).  For the other 
temperatures, heritability was not statistically significant, though that may reflect the 
low statistical power of the experimental design.  In contrast, narrow-sense heritability 
of the rhythmicity of heartbeat was much lower (range:  X to Y) and it was not 
significant at any temperature.  A perhaps surprising and provocative finding was the 
discovery that the response of heart rate to temperature was itself heritable (h2 = 0.29). 
 Robbins et al. (1999), reported a heritability of heart rate of 0.30.  In that study 
the estimate was based on variation among inbred lines, some derived from a Michigan 
population and others based on strains collected at other, widely separated geographic 
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locations.  Consequently, the earlier study gave an estimate of heritability which, if not 
species-wide, represents inter-population variability in addition to variation within a 
population.  Also, if there is substantial epistatic variance for heart rate in this species, a 
heritability estimate based on variance among inbred strains would have included this 
variance as well as additive variance.  Regression of offspring mean on parental mean 
contains a fraction (viz. ¼) of additive X additive interaction variance.  It remains to be 
determined how much genetic variance is due to epistasis.  Another difference between 
this report and that of Robbins et al. (1999),  relates to temperature.  In both studies, flies 
were cultured at 25 C, which is thought to be close to the optimal rearing temperature 
for this species (Ashburner, 1989).  However, in the present study, heart rate was 
measured at five different temperatures, and each temperature was precisely maintained, 
while Robbins et al. (1999),    presumably recorded at ambient.  Despite the 
methodological differences between the two studies, the heritabilities are reasonably 
similar.   
 Robbins et al. (1999), pointed out that the ability of a heart to beat regularly at a 
certain rate is a remarkable phenotype, and one that reflects genetic regulation.  The 
heritabilities reported here bear out this statement, especially the very low values 
measured for heartbeat rhythmicity.  Even the largest heritability we measured, for 
temperature-dependence of heart rate, the size of h2 was modest (0.29).  Natural 
selection within a population reduces the amount of additive genetic variation for the 
trait under selection.  While a paucity of additive genetic variation for a trait does not 
imply that the trait has been subjected to natural selection, the converse is true:  a large 
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amount of additive genetic variation for a trait implies that it has not been under strong 
directional selection. 
Ultimately, changes in heart rate must, perforce, be mediated through modulation 
of transmembrane potentials in the pacemaker (Bodmer et al., 2005).  This may be a 
direct effect of temperature.  In insects, the heart itself is heated or cooled according to 
ambient temperature and metabolic activity.  It may be that varying temperatures alter 
state variables of the oscillating ensemble of ion channels comprising the pacemaker.  
The activation energy estimated from the Arrhenius plot is of interest in this regard, as it 
suggests that covalent bonds are not being broken (Laidler, 1972).  The Q10 is also fairly 
low.   
Most metabolic reactions experience a rate increase when exposed to increasing 
temperatures (Sweeny & Hasting, 1960).  However, a surprising range of metabolic 
processes are seen to be unresponsive to temperature change, i.e. must be compensated 
in some way (Bullock, 1955; Winfree, 1980).  For example, circadian clock oscillators 
in Drosophila, are seen to have a nearly flat temperature response (Pittendrigh, 1954).  If 
this be the case for the heart, the pacemaker might, at least in part, be indirectly affected 
by temperature, perhaps through neurotransmitter control.  Previous work in other 
insects supports this interpretation. In order for an insect to respond to variations in both 
internal and external conditions, its heart rate must be variable and under control.  In the 
moth, circulation of haemolymph may be thermoregulatory, and increasing heart rate in 
response to raised temperatures is a result of involvement of the nervous system in 
sensing heat and controlling rate (Miller, 1985).  Heinrich (1970a,b), has demonstrated 
such thermoregulation in Manduca sexta.  When the thorax overheats, the heart responds 
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by increased pumping of hemolymph into the abdomen, a response eliminated by 
sectioning of the ventral nerve cord.  The site of the thermoregulation was traced to the 
pterothoracic ganglia in Cecropia moths by artificial thermal clamping (Hanegan, 1973).  
Desert robber flies, Promachus gigantius and Efferia texana were shown to 
thermoregulate, but with differences related to body mass (Morgan & Shelley, 1988). 
 Such putative indirect effects would likely be mediated via diffusible 
transmitters acting upon ionotropic receptors, or through networks of intracellular 
signaling pathways leading to biochemical modifications of pacemaker components 
(Bodmer et al., 2005).  The neurotransmitters norepinephrine, serotonin, dopamine, and 
acetylcholine are cardioacceleratory (Johnson et al., 1997).  Limulus GHSLLHFamide  
(Gaus et al., 1994; Johnson et al., 2000; Bodmer et al., 2005).  The catecholamines may 
act through G-Protein coupled receptors, which is the case in vertebrates (Hartzell, 1988; 
Trautwein & Hescheler, 1990).  cGMP is implicated in at least one control pathway as 
non-hydrolyzable forms (Brautigan & Pinault, 1991) increase heart rate in the fly 
(Johnson et al., 2002).  Drosophila homozygous for the sitter allele of the foraging gene 
(Sokolowski, 2001; de Belle et al., 1989), which encodes a cGMP-dependent kinase 
(Osborne et al., 1997), have accelerated heart rate (Johnson et al., 2002).  Heart 
Rhythmicity Index was affected by pertussis toxin and by agonists and antagonists of 
both  adrenergic and 5-HT2 receptors; this suggests involvement of two different types 
of G proteins (Johnson et al., 2002).  Pacemaker sensitivity to serotonin was eliminated 
in animals heterozygous for the homozygous-lethal mutation l(4)16, an allele of the gene 
that encodes CaM-kinase-II (Hochman, 1971; Cho et al., 1991; Ohsako et al., 1993; 
Griffith et al., 1993). Norepinephrine sensitivity was unaffected (Johnson et al., 2002).  
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Identical results were obtained when flies were treated with the CaM-kinase-II inhibitor 
KN-93 (Johnson et al., 2002).     
White et al. (1992) tested for effects of heavy water consumption (water 
containing deuterium, 1H
2, or D2O) and temperature change on heart rate.  D2O reduced 
heart rate at all temperatures tested.  Heart rate rose linearly between 18 and 33 in flies 
drinking protonated water.  This held for D2O concentrations of 20% and 40%, but the 
D2O reduced the sensitivity to the temperature changes as the slopes flattened 
proportionally at each concentration indicating an interaction between the two 
treatments of an unknown nature.   
Human cardiovascular function is influenced by multiple genetic factors and 
knowing about the underlying genetic variation in these traits can be useful in medicine 
and health care (Broeckel & Schork, 2004; Lusis et al., 2004; Wilson & Olden, 2004).  
Findings in the fly are directly applicable to the human heart as a growing number of 
genes have been identified with homologous function in both organisms (Bodmer et al., 
2005).     
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